

Connecting via Winsock to STN

Trying 3106016892...Open

Welcome to STN International! Enter x:X

LOGINID:sssptal626kas

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Sep 17	IMSworld Pharmaceutical Company Directory name change to PHARMASEARCH
NEWS	3	Oct 09	Korean abstracts now included in Derwent World Patents Index
NEWS	4	Oct 09	Number of Derwent World Patents Index updates increased
NEWS	5	Oct 15	Calculated properties now in the REGISTRY/ZREGISTRY File
NEWS	6	Oct 22	Over 1 million reactions added to CASREACT
NEWS	7	Oct 22	DGENE GETSIM has been improved
NEWS	8	Oct 29	AAASD no longer available
NEWS	9	Nov 19	New Search Capabilities USPATFULL and USPAT2
NEWS	10	Nov 19	TOXCENTER(SM) - new toxicology file now available on STN
NEWS	11	Nov 29	COPPERLIT now available on STN
NEWS	12	Nov 29	DWPI revisions to NTIS and US Provisional Numbers
NEWS	13	Nov 30	Files VETU and VETB to have open access
NEWS	14	Dec 10	WPINDEX/WPIDS/WPIX New and Revised Manual Codes for 2002
NEWS	15	Dec 10	DGENE BLAST Homology Search
NEWS	16	Dec 17	WELDASEARCH now available on STN
NEWS	17	Dec 17	STANDARDS now available on STN
NEWS	18	Dec 17	New fields for DPCI
NEWS	19	Dec 19	CAS Roles modified
NEWS	20	Dec 19	1907-1946 data and page images added to CA and Cplus
NEWS	21	Jan 25	BLAST(R) searching in REGISTRY available in STN on the Web
NEWS	22	Jan 25	Searching with the P indicator for Preparations
NEWS	23	Jan 29	FSTA has been reloaded and moves to weekly updates
NEWS	24	Feb 01	DKILIT now produced by FIZ Karlsruhe and has a new update frequency
NEWS	25	Feb 19	Access via Tymnet and SprintNet Eliminated Effective 3/31/02
NEWS	26	Mar 08	Gene Names now available in BIOSIS
NEWS	EXPRESS		February 1 CURRENT WINDOWS VERSION IS V6.0d, CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP), AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
NEWS	HOURS		STN Operating Hours Plus Help Desk Availability
NEWS	INTER		General Internet Information
NEWS	LOGIN		Welcome Banner and News Items
NEWS	PHONE		Direct Dial and Telecommunication Network Access to STN
NEWS	WWW		CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

Kamal Saeed

FILE 'HOME' ENTERED AT 09:23:28 ON 19 MAR 2002

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.15

0.15

FILE 'REGISTRY' ENTERED AT 09:23:37 ON 19 MAR 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 17 MAR 2002 HIGHEST RN 401569-84-4

DICTIONARY FILE UPDATES: 17 MAR 2002 HIGHEST RN 401569-84-4

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES
for more information. See STNnote 27, Searching Properties in the CAS
Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

The P indicator for Preparations was not generated for all of the
CAS Registry Numbers that were added to the H/Z/CA/CAPLUS files between
12/27/01 and 1/23/02. Use of the P indicator in online and SDI searches
during this period, either directly appended to a CAS Registry Number
or by qualifying an L-number with /P, may have yielded incomplete results.
As of 1/23/02, the situation has been resolved. Also, note that searches
conducted using the PREP role indicator were not affected.

Customers running searches and/or SDIs in the H/Z/CA/CAPLUS files
incorporating CAS Registry Numbers with the P indicator between 12/27/01
and 1/23/02, are encouraged to re-run these strategies. Contact the
CAS Help Desk at 1-800-848-6533 in North America or 1-614-447-3698,
worldwide, or send an e-mail to help@cas.org for further assistance or to
receive a credit for any duplicate searches.

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=>

Uploading C:\Program Files\Stnexp\Queries\099226311.str

L1 STRUCTURE UPLOADED

=> que L1


L2 QUE L1

=> d

L2 HAS NO ANSWERS

Kamal Saeed

L1 STR



Structure attributes must be viewed using STN Express query preparation.

L2 QUE ABB=ON PLU=ON L1

=> s l1

SAMPLE SEARCH INITIATED 09:24:04 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 22108 TO ITERATE

4.5% PROCESSED 1000 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 433292 TO 451028
PROJECTED ANSWERS: 86608 TO 94676

L3 50 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 09:24:19 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 441969 TO ITERATE

90.5% PROCESSED 400000 ITERATIONS 82006 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.13

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 441969 TO 441969
PROJECTED ANSWERS: 89709 TO 91511

L4 82006 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	140.86	141.01

FILE 'CAPLUS' ENTERED AT 09:25:16 ON 19 MAR 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Kamal Saeed

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Mar 2002 VOL 136 ISS 12
FILE LAST UPDATED: 18 Mar 2002 (20020318/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

The P indicator for Preparations was not generated for all of the CAS Registry Numbers that were added to the CAS files between 12/27/01 and 1/23/02. As of 1/23/02, the situation has been resolved. Searches and/or SDIs in the H/Z/CA/CAplus files incorporating CAS Registry Numbers with the P indicator executed between 12/27/01 and 1/23/02 may be incomplete. See the NEWS message on this topic for more information.

=> s l4
L5 17361 L4

=>Testing the current file..... screen

Your upload attempt failed, please try again

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.34	142.35

FILE 'REGISTRY' ENTERED AT 09:27:48 ON 19 MAR 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 17 MAR 2002 HIGHEST RN 401569-84-4
DICTIONARY FILE UPDATES: 17 MAR 2002 HIGHEST RN 401569-84-4

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Kamal Saeed

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

The P indicator for Preparations was not generated for all of the CAS Registry Numbers that were added to the H/Z/CA/CAplus files between 12/27/01 and 1/23/02. Use of the P indicator in online and SDI searches during this period, either directly appended to a CAS Registry Number or by qualifying an L-number with /P, may have yielded incomplete results. As of 1/23/02, the situation has been resolved. Also, note that searches conducted using the PREP role indicator were not affected.

Customers running searches and/or SDIs in the H/Z/CA/CAplus files incorporating CAS Registry Numbers with the P indicator between 12/27/01 and 1/23/02, are encouraged to re-run these strategies. Contact the CAS Help Desk at 1-800-848-6533 in North America or 1-614-447-3698, worldwide, or send an e-mail to help@cas.org for further assistance or to receive a credit for any duplicate searches.

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=>

Uploading C:\Program Files\Stnexp\Queries\099226311.str

L6 STRUCTURE UPLOADED

=> que L6

L7 QUE L6

=> s 17

SAMPLE SEARCH INITIATED 09:28:24 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 22108 TO ITERATE

4.5% PROCESSED 1000 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 433292 TO 451028

PROJECTED ANSWERS: 34131 TO 39267

L8 50 SEA SSS SAM L6

=> s 17 full

FULL SEARCH INITIATED 09:28:37 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 441969 TO ITERATE

90.5% PROCESSED 400000 ITERATIONS 30352 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.07

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 441969 TO 441969

Kamal Saeed

PROJECTED ANSWERS: 32987 TO 34085

L9 30352 SEA SSS FUL L6

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

140.54

282.89

FILE 'CAPLUS' ENTERED AT 09:29:12 ON 19 MAR 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Mar 2002 VOL 136 ISS 12

FILE LAST UPDATED: 18 Mar 2002 (20020318/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

The P indicator for Preparations was not generated for all of the CAS Registry Numbers that were added to the CAS files between 12/27/01 and 1/23/02. As of 1/23/02, the situation has been resolved. Searches and/or SDIs in the H/Z/CA/CAPLUS files incorporating CAS Registry Numbers with the P indicator executed between 12/27/01 and 1/23/02 may be incomplete. See the NEWS message on this topic for more information.

=> s l9

L10 5482 L9

=> d ibib hitstr abs 1-30

L10 ANSWER 1 OF 5482 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:157831 CAPLUS
TITLE: Human coactivator of nuclear receptors COASTER, protein and cDNA sequence, tissue distribution and uses in modulation of transcription activity
INVENTOR(S): Dechering, Koen Jacob; Mosselman, Sietse
PATENT ASSIGNEE(S): Akzo Nobel N.V., Neth.
SOURCE: PCT Int. Appl., 78 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002016426	A2	20020228	WO 2001-EP9499	20010816

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LJ, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GH, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: EP 2000-202905 A 20000821
EP 2001-201771 A 20010514

IT INDEXING IN PROGRESS
IT 84449-90-1, Raloxifene
RL: ANT (Analyte); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study)
(as agonist on ER.alpha.; human coactivator of nuclear receptors COASTER, protein and cDNA sequence, tissue distribution and uses in modulation of transcription activity)
RN 84449-90-1 CAPLUS
CN Methanone, [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




AB The invention provides a protein COASTER which is found to be a coactivator of nuclear receptor. The invention also relates to use of a said protein COASTER in an assay to identify nuclear receptor modulator, preferably a steroid receptor. The invention also relates to method of modulation of transcriptional activity promoted by a responsive nuclear receptor, preferably a steroid receptor and a coactivator COASTER. The invention demonstrates that amino acids 1 to 234 of said protein COASTER are sufficient for coactivating potential of COASTER on the raloxifene or 4OH-tamoxifen liganded ER.alpha.. The invention also demonstrates that raloxifene acts as an agonist on ERE-driven gene transcription in the presence of ER.alpha. and COASTER. The invention further demonstrates

L10 ANSWER 2 OF 5482 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:151555 CAPLUS
TITLE: Preparation of O-substituted 4-(4-hydroxyphenyl)-1,1,1-trifluoro-2-butanones as selective cPLA2 inhibitors
INVENTOR(S): Benville, Jacques; Gai, Yonghua; Johnson, Graham; Zusi, Fred Christopher; Burke, James R.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: U.S., 112 pp., Cont.-in-part of U.S. 6,255,496.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6350892	B1	20020226	US 2000-507782	20000218
US 6255496	B1	20010703	US 1999-300111	19990427

PRIORITY APPLN. INFO.: US 1997-59597P P 19970923
US 1997-63518P P 19971027
US 1998-151002 B1 19980910
US 1999-300111 A2 19990427

IT 221912-85-2P, 2-Butanone, 1,1,1-trifluoro-4-[4-[2-(4-(phenylmethyl)-1-piperidinyl)ethoxy]phenyl]-, hydrochloride
221912-86-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of O-substituted 4-(4-hydroxyphenyl)-1,1,1-trifluoro-2-butanones as selective cPLA2 inhibitors)
RN 221912-85-2 CAPLUS
CN 2-Butanone, 1,1,1-trifluoro-4-[4-[2-(4-(phenylmethyl)-1-piperidinyl)ethoxy]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 221912-86-3 CAPLUS
CN 2-Butanone, 1,1,1-trifluoro-4-[4-[2-(4-(octyloxy)-1-piperidinyl)ethoxy]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)

L10 ANSWER 1 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)
that 4OH-tamoxifen acts as an agonist on the transcriptional activity of ER.alpha., not ER.beta..

L10 ANSWER 2 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)



● HCl

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. 1 [R5 = alk(en/yn)yl, alkoxy, alkylthio, halo, hydroxy, etc.; p = 0-2; V1 = O, SO-2, NHC=O, C=ONH; R3-4 = H, Me; R1-2 = when taken together form an oxo group or R1-2 = H, OH; Y1 = O, SO-2, aza, etc.] were prep'd. E.g., 4-(3-hydroxypropyl)phenol was converted to Me [4-(3-methanesulfonyloxypropyl)phenoxy]acetate in 4 steps. This intermediate was reacted with N-methyl-2,2-[di(4-chlorophenyl)]ethylamine (CH3CN, NaI, 80.degree.C, 18 h) to give the corresponding tertiary amine. The amine was treated with trifluoromethyltrimethylsilane (PhMe, -55.degree.C) to give isolated acetal II. Hydrolysis of II (THF, HClaq) provided the example compd. trifluoromethylketone isolated as the hydrochloride. Compds. 1, presented in examples, showed IC50 of 1-50 .mu.M against cPLA2.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE


FORMAT

L10 ANSWER 3 OF 5482 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 2002:143805 CAPLUS
 DOCUMENT NUMBER: 136:151075
 TITLE: Process for preparing N-(4-piperidinyl)benzamide derivative and novel benzoic acid active thioester as an intermediate
 INVENTOR(S): Yun, Seong Jun; Jeong, Yong Ho; Lee, Chi Uh; Oh, Yun Seok; Lim, Jae Kyoung; Kim, Ik Hae; Kim, Dong Seok
 PATENT ASSIGNEE(S): Yansen Korea Co., Ltd., S. Korea; Dong Wha Pharm. Ind.
 SOURCE: Co., Ltd.
 Repub. Korean Kongkae Taeho Kongbo, No pp. given
 CODEN: KRXXA7
 DOCUMENT TYPE: Patent
 LANGUAGE: Korean
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
KR 2000020793	A	20000415	KR 1998-39547	19980924

OTHER SOURCE(S): CASREACT 136:151075
 IT 104860-26-6, cis-4-Amino-3-methoxy-1-[3-(4-fluorophenoxy)propyl]piperidine
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (process for prep. N-(4-piperidinyl)benzamide deriv. by amidation of benzoic acid active thioester and aminopiperidine deriv.)
 RN 104860-26-6 CAPLUS
 CN 4-Piperidinamine, 1-[3-(4-fluorophenoxy)propyl]-3-methoxy-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 81098-60-4P, cis-2-Methoxy-4-amino-5-chloro-N-[1-[3-(4-fluorophenoxy)propyl]-3-methoxy-4-piperidinyl]benzamide
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (process for prep. N-(4-piperidinyl)benzamide deriv. by amidation of benzoic acid active thioester and aminopiperidine deriv.)
 RN 81098-60-4 CAPLUS
 CN Benzamide, 4-amino-5-chloro-N-[1-[3-(4-fluorophenoxy)propyl]-3-methoxy-4-piperidinyl]-2-methoxy-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

L10 ANSWER 4 OF 5482 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 2002:142672 CAPLUS
 TITLE: Preparation of biphenylcarboxamidoisoindoline derivatives as apolipoprotein B secretion inhibitors
 INVENTOR(S): Yamada, Harutami; Ando, Akira; Kawanishi, Hiroyuki; Nagata, Koichi; Yasuhara, Mikiko
 PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 149 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002014277	A1	20020221	WO 2001-JP6844	20010809


W: AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CO, CR, CU, CZ, DM, DZ, EC, EE, GE, GR, HR, HU, ID, IL, IN, IS, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 PRIORITY APPLN. INFO.: JP 2000-243004 A 20000810
 JP 2001-172918 A 20010607

IT 400726-32-9P 400726-27-4P 400726-33-1P
 RL: IMP (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of biphenylcarboxamidoisoindoline deriva. as apolipoprotein B secretion inhibitors)
 RN 400726-22-9 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED



RN 400726-27-4 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED


L10 ANSWER 3 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)



AB An N-(4-piperidinyl)benzamide is prepd. by the reaction of thioester and cis-piperidine amine deriva., which has gastroenteric stimulating activity. A carboxylic deriv. and alkyl chloroformate are reacted to give an intermediate, and reacted with 2-mercaptobenzimidazole to give the novel active thioester. The active thioester and cis-piperidine amine deriva. are condensed to give N-(4-piperidinyl)benzamide deriva. having a set of substituents including Cl-6 lower alkyl and an alkyl or aryloxyalkyl. Thus, 376 mg of triethylamine and 280 mg of Et chloroformate were added to 500 mg 4-amino-5-chloro-2-methoxybenzoic acid and reacted at 0-10.degree. for 1.5 h, and treated with 396 mg 2-mercaptobenzimidazole at room temp. for 6 h to give an active thioester.
 A mixed soln. of 630 mg of cis-4-amino-3-methoxy-1-[3-(4-fluorophenoxy)propyl]piperidine and 1 mL DMF was added to the thioester and allowed to react at room temp. for 5 h to give 963 mg of


cis-2-methoxy-4-amino-5-chloro-N-[1-[3-(4-fluorophenoxy)propyl]-3-methoxy-4-piperidinyl]benzamide monohydrate.

L10 ANSWER 4 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 400726-32-1 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED


PAGE 1-A



PAGE 1-B




IT 400727-24-4P 400727-28-8P 400727-30-3P
 RL: IMP (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. of biphenylcarboxamidoisoindoline deriva. as apolipoprotein B secretion inhibitors)
 RN 400727-24-4 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 6-[2-(4-morpholinyl)ethoxy]-4'-(trifluoromethyl)-, sodium salt (9CI) (CA INDEX NAME)




● Na

RN 400727-28-8 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 6-[2-(4-methyl-1-piperazinyl)ethoxy]-4'-(trifluoromethyl)-, sodium salt (9CI) (CA INDEX NAME)




● Na

RN 400727-30-2 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 6-[2-(1-pyrrolidinyl)ethoxy]-4'-(trifluoromethyl)-, sodium salt (9CI) (CA INDEX NAME)



● Na

GI



I

AB The title compds. I [ring A is a substituted or unsubstituted benzene ring; ring B is a substituted or unsubstituted benzene ring; Q is CO or CH₂; and R is a substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted carbamoyl, a substituted or unsubstituted heterocyclic group, substituted or unsubstituted aryl, or the like], useful as apolipoprotein B secretion inhibitors (no data), are prepd. Processes for the prepn. of I are claimed. For example, 2-(2-pyridyl)acetyl-5-[2-(4-trifluoromethylphenyl)benzoylamino]isoindoline was prepd.

REFERENCE COUNT: 77 THERE ARE 77 CITED REFERENCES AVAILABLE FOR THIS

FORMAT

RECORD. ALL CITATIONS AVAILABLE IN THE RE

ACCESSION NUMBER: 2002:142668 CAPLUS

DOCUMENT NUMBER: 136:183704

TITLE: Indoline derivatives as 5-HT_{2C} antagonists, useful as anxiolytics and antidepressants

INVENTOR(S): Bromidge, Steven Mark; Lovell, Peter John; Moss, Stephen Frederick; Serafinowska, Halina Teresa

PATENT ASSIGNEE(S): Smithkline Beecham P.L.C., UK

SOURCE: PCT Int. Appl., 62 pp.

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002014273	A1	20020221	WO 2001-EP9273	20010809
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: GB 2000-19950 A 20000812


IT 399579-32-9P, (E)-3-(2-Chlorophenyl)-1-[5-methoxy-6-[2-(4-(2-phenoxyethyl)piperazin-1-yl)ethoxy]-2,3-dihydroindol-1-yl]prop-2-en-1-one
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; prepn. of indoline deriva. as 5-HT_{2C} antagonists)

RN 399579-32-9 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.



IT 170229-79-5P, 4-Methoxy-3-(2-(piperidin-1-yl)ethoxy)phenylamine
170229-80-8P, 4-Methoxy-3-(2-morpholinoethoxy)phenylamine
170229-91-1P, 1-[2-(2-Methoxy-5-nitrophenoxy)ethyl]pyrrolidine
170229-92-3P, 4-Methoxy-3-[2-(pyrrolidin-1-yl)ethoxy]phenylamine
399579-80-7P, 1-[2-(2-Methoxy-5-nitrophenoxy)ethyl]piperidine
399579-81-6P, 4-[2-(2-Methoxy-5-nitrophenoxy)ethyl]morpholine
399579-82-9P, (2,2-Dimethoxyethyl) [4-methoxy-3-(2-(piperidin-1-yl)ethoxy)phenyl]amine
399579-83-0P, (2,2-Dimethoxyethyl) [4-methoxy-3-(2-(pyrrolidin-1-yl)ethoxy)phenyl]amine
399579-84-1P, (2,2-Dimethoxyethyl) [4-methoxy-3-(2-morpholinoethoxy)phenyl]amine
399580-22-4P, 4-[2-(2-Methoxy-5-nitrophenoxy)ethyl]piperazine-1-carboxylic acid tert-butyl ester
399580-23-5P,


Kamal Saeed

4-[2-(5-Amino-2-methoxyphenoxy)ethyl]piperazine-1-carboxylic acid tert-butyl ester 399580-24-6P, 4-[2-[5-(2,2-Dimethoxyethylamino)-2-methoxyphenoxy]ethyl]piperazine-1-carboxylic acid tert-butyl ester 399580-42-8P, (2,2-Dimethoxyethyl) [4-fluoro-3-(2-(piperidin-1-yl)ethoxy)phenyl]amine 399580-43-9P, N-(2,2-Dimethoxyethyl)-2,2,2-trifluoro-N-[4-fluoro-3-(2-(piperidin-1-yl)ethoxy)phenyl]acetamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; prepn. of indoline deriva. as 5-HT_{2C} antagonists)


RN 170229-79-5 CAPLUS

CN Benzenamine, 4-methoxy-3-[2-(1-piperidinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 170229-80-8 CAPLUS

CN Benzenamine, 4-methoxy-3-[2-(4-morpholinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 170229-91-1 CAPLUS

CN Pyrrolidine, 1-[2-(2-methoxy-5-nitrophenoxy)ethyl]- (9CI) (CA INDEX NAME)




L10 ANSWER 5 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)


RN 170229-92-2 CAPLUS
CN Benzenamine, 4-methoxy-3-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 399579-80-7 CAPLUS
CN Piperidine, 1-[2-(2-methoxy-5-nitrophenoxy)ethyl]- (9CI) (CA INDEX NAME)




RN 399579-81-8 CAPLUS
CN Morpholine, 4-[2-(2-methoxy-5-nitrophenoxy)ethyl]- (9CI) (CA INDEX NAME)




RN 399579-82-9 CAPLUS
CN Benzenamine, N-(2,2-dimethoxyethyl)-4-methoxy-3-[2-(1-piperidinyl)ethoxy]- (9CI) (CA INDEX NAME)




L10 ANSWER 5 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 399580-23-5 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-(5-amino-2-methoxyphenoxy)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 399580-24-6 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-[5-[(2,2-dimethoxyethyl)amino]-2-methoxyphenoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 399580-42-8 CAPLUS
CN Benzenamine, N-(2,2-dimethoxyethyl)-4-fluoro-3-[2-(1-piperidinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 399580-43-9 CAPLUS
CN Acetamide, N-(2,2-dimethoxyethyl)-2,2,2-trifluoro-N-[4-fluoro-3-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)

Kamal Saeed


L10 ANSWER 5 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 399579-83-0 CAPLUS
CN Benzenamine, N-(2,2-dimethoxyethyl)-4-methoxy-3-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 399579-84-1 CAPLUS
CN Benzenamine, N-(2,2-dimethoxyethyl)-4-methoxy-3-[2-(4-morpholinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 399580-22-4 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-(2-methoxy-5-nitrophenoxy)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




L10 ANSWER 5 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)



GI



I




II

AB The invention relates to novel cinnamide compds., which have 5-HT2C antagonist activity, of formula I, or pharmaceutically acceptable salts thereof (in which: ring Q is Ph or naphthyl; R1 is halo, Cl-6 alkyl, Cl-6 alkoxy, Cl-6 alkylthio, OH, (di) (Cl-6alkyl)amino, NO2, CN, CF3, OCF3, aryl, arylCl-6alkyl, arylCl-6alkyloxy or arylCl-6alkylthio; m is 0-5; R2 and R3 are independently H or Cl-6alkyl; R4 is H, halo, Cl-6alkyl, Cl-6alkoxy, aryl, cyano, haloCl-6alkyl or OCF3; Z is C or N; R5 is either: (i) a group NR6R7 where R6 and R7 are independently H, (un)substituted Cl-6alkyl; or (ii) (un)substituted N-linked heterocycle; or (iii) an (un)substituted C-linked heterocycle; n = 0-3, provided that n is not 0 when R5 is a group (i) or (ii); dashed line is an optional double bond, where X and Y are independently CR8R9 (when single bond) or CR10 (when double bond); wherein R8, R9 and R10 are independently H or Cl-6alkyl). Also disclosed are processes for prepn. of I, compns. contg. them, and their use in the treatment of CNS and other disorders. In particular, their use for treating anxiety and/or depression is claimed. A total of

L10 ANSWER 5 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)
 171 examples and 73 intermediate preps. are given. For instance, 2-methoxy-5-nitrophenol was etherified with 1-(2-chloroethyl)piperidine-HCl (70%), followed by hydrogenation of nitro to amino (100%), reductive alkylation of amino with (MeO)2CHCHO (88%), cyclization to form an indole (73%), redn. to give an indoline (72%), and N-coupling with 2-chlorocinnamic acid (40%), to give preferred (as HCl salt) invention compd. (E)-11. In a test for inhibition of [3H]-mesergine binding at human 5-HT2C clones expressed in HEK 293 cells in vitro, 1 had pKi values in the range of 7.5-9.8.
 REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT


L10 ANSWER 6 OF 5482 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 2002:142664 CAPLUS
 DOCUMENT NUMBER: 136:183713
 TITLE: Preparation of 2,4-substituted pyridine derivatives as agonists, antagonists or inverse agonists for GABAA brain receptors or their prodrugs
 INVENTOR(S): S.; Hutchison, Alan
 Kevin Neurogen Corporation, USA
 PATENT ASSIGNEE(S): PCT Int. Appl., 110 pp.
 SOURCE: CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE
 WO 2002014269 A2 20020221 WO 2001-US41757 20010816
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KS, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 PRIORITY APPLN. INFO.: US 2000-22552P P 20000816
 IT 400016-65-1P, 1-[[2-[3-(3-(N-Pyrrolidinyl)propoxy)phenyl]-4-quinolinyl]carbonyl]pyrrolidine 400016-68-4P
 1-[[2-[3-(2-Imidazol-1-ylethoxy)phenyl]-4-quinolinyl]carbonyl]pyrrolidine
 RL: ARG (Analytical reagent use); DGM (Diagnostic use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of 2,4-substituted pyridine derivs. as agonists, antagonists or inverse agonists for GABAA brain receptors or prodrugs)
 RN 400016-65-1 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 400016-68-4 CAPLUS

L10 ANSWER 6 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)
 CN INDEX NAME NOT YET ASSIGNED



GI



AB Disclosed are compds. (I); (R)-1-[[2-(3,4-difluorophenyl)-4-quinolinyl]carbonyl]-2-hydroxymethylpyrrolidine (1) or pharmaceutically acceptable salts thereof wherein: II represents III-VI; A, B, D and G are N or CR1; E = O, S, NRS; Z = (CRaRb)n (n = 0-2); and R1, R5, Ra, Rb, and
 W are defined herein. These compds. are agonists, antagonists or inverse agonists for GABAA brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAA brain receptors and are therefore useful in the diagnosis and treatment of anxiety, depression, Down's syndrome, sleep and seizure disorders, overdose with benzodiazepine drugs and for enhancement of memory. Particularly preferred compds. have Ki values of <100 nM in a std. assay for GABAA binding affinity. Pharmaceutical compns., including packaged pharmaceutical compns., are further provided. 1 Are also useful

Kamal Saeed

L10 ANSWER 6 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)
 as probes for the localization of GABAA receptors in tissue samples.
 Only

the prepn. of 1 is included, but >100 other compds. are specifically mentioned. Intermediate 2-(3,4-difluorophenyl)-4-quinoline carboxylic acid was prepd. by heating a mixt. of 2,3-indolinedione (0.03 mol), 3',4'-difluoroacetophenone (0.03 mol) and KOH (0.05 mol) in 1,4-dioxane (50 mL) at 105.degree. for 48 h. The reaction soln. was then cooled to room temp. and concd. under reduced pressure. The residue was treated with EtOAc and extd. with H2O. The pH of the aq. layer was adjusted to 5-6 with 1N HCl, the resulting solid was collected by vacuum filtration, washed with H2O, and dried to give the intermediate (450 mg) as a yellow solid. A mixt. of the intermediate (100 mg), benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (220 mg) and (R)-(-)-pyrrolidinemethanol (0.1 mL) in 1 mL of DMF was stirred at room temp. for 18 h. The mixt. was added to satd. aq. NaHCO3 soln. and extd. three times with EtOAc. The combined EtOAc layers were washed with brine and H2O, dried over Na2SO4, filtered and concd. to afford a foam. The foam contg. 1 was purified by preparative silica gel thin layer chromatog., using 10% MeOH in CH2Cl2 as the developing solvent.


L10 ANSWER 7 OF 5482 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:142506 CAPLUS
DOCUMENT NUMBER: 136:177977
TITLE: Methods for treating inflammatory diseases using PPAR agonists
INVENTOR(S): Pershadsingh, Harrihar A.
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002013812	A1	20020221	WO 2001-US25668	20010816
W: AU, CA, MX, NZ, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				

PRIORITY APPLN. INFO.: US 2000-225907P P 20000817
US 2000-230509P P 20000906

IT 222834-30-2, (-)-DRF 2725
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(NMC 61-0029; methods for treating inflammatory diseases using PPAR agonists)
RN 222834-30-2 CAPLUS
CN Benzenepropanoic acid, .alpha.-ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




AB The present invention describes methods for the use of PPAR ligands in the treatment inflammatory endocrine, dermatol., cardiovascular immunol., neurol., ophthalmic, neoplastic, pulmonary diseases, and age-related dysregulations. In addn., methods are provided for treating said conditions and diseases comprising the step of administering to a human or an animal in need thereof a therapeutic amt. of pharmacol. compns. comprising a pharmaceutically acceptable carrier, and a PPAR.gamma. agonist which cross-activates PPAR.alpha. or PPAR.delta. or both, or a

L10 ANSWER 8 OF 5482 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:142496 CAPLUS
TITLE: Method using a rapamycin and an antiestrogen for treating estrogen receptor-positive carcinoma
INVENTOR(S): Zhang, Yixian; Sadler, Tammy Michelle; Frost, Philip; Greenberger, Lee Martin
PATENT ASSIGNEE(S): American Home Products Corporation, USA
SOURCE: PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002013802	A2	20020221	WO 2001-US24615	20010806
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2000-224326P P 20000811


IT 182133-25-1
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(LY 353381; rapamycin compd. and antiestrogen for treating estrogen receptor-pos. carcinoma)
RN 182133-25-1 CAPLUS
CN Benzo[b]thiophene-6-ol, 2-(4-methoxyphenyl)-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]- (9CI) (CA INDEX NAME)




IT 78994-23-7, Levormeloxifene 84449-90-1, Raloxifene 116057-75-1, Idoxifene 182167-03-9, EM-800 190791-29-8, CP-136156 198480-55-6 198481-32-2
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(rapamycin compd. and antiestrogen for treating estrogen receptor-pos. carcinoma)
RN 78994-23-7 CAPLUS
CN Pyrrolidine, 1-[2-[4-[(3R,4R)-3,4-dihydro-7-methoxy-2,2-dimethyl-3-phenyl-2H-1-benzopyran-4-yl]phenoxy]ethyl]- (9CI) (CA INDEX NAME)

L10 ANSWER 7 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)
PPAR.gamma. partial agonist, or a PPAR.gamma./RXR agonist, effective to reverse, slow, stop, or prevent the pathol. inflammatory or degenerative process.
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L10 ANSWER 8 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)
Absolute stereochemistry. Rotation (-).




RN 84449-90-1 CAPLUS
CN Methanone, [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 116057-75-1 CAPLUS
CN Pyrrolidine, 1-[2-[4-[(1E)-1-(4-iodophenyl)-2-phenyl-1-butenyl]phenoxy]ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 182167-03-9 CAPLUS
 CN Propanoic acid, 2,2-dimethyl-, 4-[(2S)-7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-(4-[2-(1-piperidinyl)ethoxy]phenyl)-2H-1-benzopyran-3-yl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 190791-29-8 CAPLUS
 CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)-, (2S,3S)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 180916-16-9
 CMF C28 H31 N O2

Absolute stereochemistry. Rotation (-).

L10 ANSWER 8 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)
 CN 1H-Indol-5-ol,
 1-[[4-[2-(hexahydro-1H-azepin-1-yl)ethoxy]phenyl]methyl]-2-(4-hydroxyphenyl)-3-methyl- (9CI) (CA INDEX NAME)




AB The invention provides a method of treating or inhibiting an estrogen receptor-pos. carcinoma in a mammal in need thereof, which comprises providing the mammal with an effective amt. of a combination of a rapamycin and an antiestrogen.




CM 2

CRN 147-71-7
 CMF C4 H6 O6
 CDES 1:S2:R*,R*

Absolute stereochemistry.



RN 198480-55-6 CAPLUS
 CN 1H-Indol-5-ol, 2-(4-hydroxyphenyl)-3-methyl-1-[[4-[2-(1-piperidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 198481-32-2 CAPLUS


L10 ANSWER 9 OF 5482 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:131009 CAPLUS
 DOCUMENT NUMBER: 136:161277
 TITLE: The effect of cisapride on esophageal motility and lower sphincter function in patients with gastro-esophageal reflux disease
 AUTHOR(S): Finizia, Caterina; Lundell, Lars; Cange, Lars; Ruth, Magnus
 CORPORATE SOURCE: Departments of Otorhinolaryngology and Surgery, Sahlgrenska University Hospital, Goteborg, 413 45, Swed.
 SOURCE: European Journal of Gastroenterology & Hepatology (2002). 14(1). 9-14
 CODEN: EJGHES; ISSN: 0954-691X
 PUBLISHER: Lippincott Williams & Wilkins
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 81098-60-4, Cisapride

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (effect of cisapride on esophageal motility and lower sphincter function in patients with gastro-esophageal reflux disease)

RN 81098-60-4 CAPLUS
 CN Benzamide, 4-amino-5-chloro-N-[1-[(3R,4S)-3-(4-fluorophenoxy)propyl]-3-methoxy-4-piperidinyl]-2-methoxy-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



AB Aim of this study was to evaluate the efficiency by which the 5-HT4 agonist cisapride affects important motor functions involved in the control of gastro-esophageal reflux. Thirty patients with proven gastro-esophageal reflux disease (endoscopy and 24 h pH-metry) were included in a randomized, double-blind, placebo controlled study with a cross-over design. Cisapride, 20 mg b.i.d., during 4 wk was compared with placebo. At baseline, as well as after 4 and 8 wk all patients underwent symptom assessments, sleeve manometry with concomitant esophageal pH-monitoring and an acid clearance test. Despite adequate plasma levels cisapride had no significant effect on swallow induced peristaltic amplitude, duration, propagation speed, the elicitation of secondary peristalsis nor on acid clearance. Neither the basal tone of the lower esophageal sphincter nor the no. of transient lower esophageal sphincter


L10 ANSWER 9 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)
 relaxations induced by gas distension of the stomach was affected by the
 administered dose of cisapride. Although cisapride has been alleged to
 improve symptoms as well as the esophagitis in patients with
 gastro-esophageal reflux disease, we found the compd. (20 mg b.i.d.)
 devoid of effects on important motor mechanisms involved in the
 pathogenesis of the disease.
 REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR
 THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L10 ANSWER 10 OF 5482 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 2002:126304 CAPLUS
 DOCUMENT NUMBER: 136:191769
 TITLE: Optical recording material using indocyanine dye
 INVENTOR(S): Yano, Toru; Takahata, Yoshinori; Oya, Keiji
 PATENT ASSIGNEE(S): Asahi Denka Kogyo K. K., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 16 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002052829 A2		20020219	JP 2001-136366	20010507
PRIORITY APPLN. INFO.:			JP 2000-165004	20000601

IT 400622-70-0
 RL: TEM (Technical or engineered material use); USES (Uses)
 (optical recording material using indocyanine dye)
 RN 400622-70-0 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED


CM 1
 CRN 400622-69-7
 CMP C49 H50 F N2 O



CM 2
 CRN 14797-73-0
 CMP C1 O4



L10 ANSWER 10 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)
 G1



AB The optical recording material contains an indocyanine dye I [A, B =
 (substituted) benzene or naphthalene ring; C = (substituted) 3- to
 6-membered ring which may contain O, S, or N; R1-2 = C1-4 alkyl which may
 form a ring; Q = Q1-2; X = H, halo; Y = org. group; Ann- = m-valent
 anion:
 m = 1, 2; p = no. to neutralize the mol]. The material is recordable by
 620-830 nm laser beam and useful for DVDR and CDR.


L10 ANSWER 11 OF 5482 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 2002:123193 CAPLUS
 DOCUMENT NUMBER: 136:179823
 TITLE: Characterization, expression and sequence of human
 lysyl oxidase EER-7 and use of EER-7 for identifying
 estrogen receptor ligands
 INVENTOR(S): Evans, Mark J.; Scicchitano, Marshall S.; Bapat,
 Ashok
 R.; Beer, Eric; Bhat, Ramesh A.; Ferris, Elissa;
 Mastroeni, Robert; Zhang, Jianzhong; Karathanasis,
 Sotirios K.
 PATENT ASSIGNEE(S): American Home Products Corporation, USA
 SOURCE: PCT Int. Appl., 68 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002012470	A2	20020214	WO 2001-US24942	20010808

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
 RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ,
 VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CP, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 PRIORITY APPLN. INFO.:

US 2000-223763P P 20000808
 US 2000-255838P P 20001215

IT 198480-55-6
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (characterization, expression and sequence of human lysyl oxidase
 EER-7
 and use of EER-7 for identifying estrogen receptor ligands)
 RN 198480-55-6 CAPLUS
 CN 1H-Indol-5-ol, 2-(4-hydroxyphenyl)-3-methyl-1-[[4-[2-(1-
 piperidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



AB The present invention relates to a novel human lysyl oxidase termed
 EER-7.


L10 ANSWER 11 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)
The invention relates to the protein and nucleic acids encoding the protein. The cDNA sequence and the encoded amino acid sequence of EER-7 are disclosed. Expression of EER-7 is regulated by estrogen. The nucleic acid sequence of EER-7 shows homol. to known lysyl oxidase genes. The invention further relates to an assay system to identify compds. that selectively modulate EER-7 protein activity by interaction with estrogen receptors.

L10 ANSWER 12 OF 5482 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:123169 CAPLUS
DOCUMENT NUMBER: 136:183807
TITLE: Heterocyclic annulated carboxylpyrroles as ligands for altering the signal transducing activity of GABAA receptors
INVENTOR(S): Maynard, George; Yohannes, Daniel; Yuan, Jun; Xie, Linghong; Ghosh, Manuka; Luke, George P.; Liu, Xiaojun; Nagel, Arthur Adam; Vincent, Lawrence
Albert;
PATENT ASSIGNEE(S): Currie, Kevin S.; Wang, Zhe-Qing; Lee, Kyungae
Neurogen Corporation, USA; Pfizer, Inc.; et al.
SOURCE: PCT Int. Appl., 397 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002012442	A2	20020214	WO 2001-US41572	20010806
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.: US 2000-223669P P 20000807				
IT 398119-64-7P 398119-88-5P 398124-23-7P 398124-25-9P 398124-29-3P 398124-30-6P 398124-31-7P				
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
(target compds.; prepn. of heterocyclic annulated carboxylpyrroles as GABAA receptor ligands via cyclocondensation reactions)				
RN 398119-64-7 CAPLUS				
CN INDEX NAME NOT YET ASSIGNED				

L10 ANSWER 12 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-A




PAGE 2-A




RN 398119-88-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

L10 ANSWER 12 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)


PAGE 1-A



PAGE 2-A




RN 398124-23-7 CAPLUS
CN 4H-Pyrrolo[3,2-e]benzothiazole-8-carboxamide, 5,6-dihydro-N-[4-(3-(1H-imidazol-1-yl)propoxy)phenyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 398124-25-9 CAPLUS
CN 4H-Pyrrolo[3,2-e]benzothiazole-8-carboxamide, 5,6-dihydro-N-[4-[2-(1H-imidazol-1-yl)ethoxy]phenyl]-2-methyl- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-A




PAGE 2-A




RN 398124-31-7 CAPLUS
CN 4H-Pyrrolo[3,2-e]benzothiazole-8-carboxamide, N-[3-fluoro-4-[2-(1-piperidinyl)ethoxy]phenyl]-5,6-dihydro-2-methyl- (9CI) (CA INDEX NAME)

PAGE 2-A




RN 398124-29-3 CAPLUS
CN 4H-Pyrrolo[3,2-e]benzothiazole-8-carboxamide, N-[3-fluoro-4-[2-(4-morpholinyl)ethoxy]phenyl]-5,6-dihydro-2-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 398124-30-6 CAPLUS
CN 4H-Pyrrolo[3,2-e]benzothiazole-8-carboxamide, 5,6-dihydro-2-methyl-N-[4-[2-



PAGE 1-A



PAGE 2-A



GI



AB Title compds. I [R1 = H, OH, amino, alkylamino, alkyl or alkoxy; R2R3 together with the atom they are attached to form (un)substituted heterocyclic ring; R4 = GQ(CH2)mN(CH2)mZ {wherein G = O or NH; Q = (un)satd. carbocyclic or heterocyclic group where each group has from 1-3

L10 ANSWER 12 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)
 rings; W = bond, O, NH, S, etc.; Z = H, OH, hydroxyalkyl, alkoxy, amino, etc.; n = 0, 1, 2 or 3 and m = 0, 1, 2 or 3; R5 = R1, halo; Y = C or CH;
 V = N, C, or CH; J = (CR6R7)d where d = 0 or 1 and R6 and R7 together form
 a carbonyl group or R6 and R7 are independently H, NO2, CN, amino, aryl, etc.; E = (un)subst.-(un)substituted alkyl or heteroalkyl chain of 0-3 atoms and the pharmaceutically acceptable salts thereof are prepd. and disclosed as ligands for GABAA receptors. Thus, II was prepd. in 10 steps from p-nitrophenylethylamine with each heterocyclic ring being formed via cyclocondensation reactions. I are highly selective agonists, antagonists or inverse agonists for GABAA brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAA brain receptor (no data). As agonists, antagonists or inverse agonists for GABAA brain receptors the compds. of the invention may be useful for treating anxiety, depression, sleep disorders, or Alzheimer's dementia.

L10 ANSWER 13 OF 5482 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 2002:123007 CAPLUS
 DOCUMENT NUMBER: 136:183816
 TITLE: Combinatorial preparation of bicyclo pyrazoles as kinase inhibitors for treatment of cancer and other proliferative disorders
 INVENTOR(S): Fancelli, Daniele; Pittala, Valeria; Varasi, Mario
 PATENT ASSIGNEE(S): Pharmacia & Upjohn S.p.A., Italy
 SOURCE: PCT Int. Appl., 331 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002012242	A2	20020214	WO 2001-EP8639	20010725
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.: US 2000-635914 A 20000810				
IT 398492-21-2P 398492-32-5P				
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses) (kinase inhibitor; combinatorial prepn. of bicyclo pyrazoles as kinase inhibitors for treatment of cancer and other proliferative disorders)				
RN 398492-21-2 CAPLUS				
CN Benzamide, 4-(1,1-dimethylethyl)-N-(1,4,5,6-tetrahydro-5-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]acetyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)				

PAGE 1-A




PAGE 1-B



RN 398492-32-5 CAPLUS
 CN Benzamide, 4-phenoxymethyl-N-(1,4,5,6-tetrahydro-5-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]acetyl]pyrrolo[3,4-c]pyrazol-3-yl]- (9CI) (CA INDEX NAME)

L10 ANSWER 13 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)


PAGE 1-A



PAGE 1-B



GI



AB Title compds. I [wherein R and R1 = independently H or (un)substituted R', COR', CONHR', CONR'R'', NHC(:NH)NHR', C(:NH)NHR', SO2R', SO2NHR', or SO2NR'R''; R' and R'' = independently H or (un)substituted (cyclo)alkyl, or aryl(alkyl); or R'R'' = alkylene chain; Ra, Rb, Rc, and Rd = independently H or (un)substituted alkyl, aryl(alkyl), or CH2OR'; or Ra and Rb and/or Rc and Rd taken together with the C to which they are bonded = (un)substituted cycloalkyl; m and n = independently 0-2, provided that m + n = 1 to 2; and pharmaceutically acceptable salts thereof] were prepd., primarily by solid phase combinatorial methods, as protein kinase inhibitors (no data). For example, cycloaddn. of H2NNH2.bul.HCl to tert-Bu 3-cyano-4-oxo-1-pyrrolidinecarboxylate (prepn. given) afforded 3-amino-5-(tert-butoxycarbonyl)-4,6-dihydropyrrolo[3,4-c]pyrazole (31%). The pyrrolopyrazole was dissolved in anhyd. CH2Cl2 and linked to methylisocyanate polystyrene resin to give the polymer-bound urea. The resin-supported urea was partitioned into 96 batches and reacted with acyl chlorides. A second partition of one of the lots, followed by reaction with carboxylic acids, sulfonyl chlorides, and isocyanates and hydrolytic cleavage from the resin, afforded combinatorial libraries of functionalized derivs., including II. I are useful for treating diseases linked to dysregulated protein kinases, such as cancer, cell proliferative

Kamal Saeed

L10 ANSWER 13 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)
 disorders, Alzheimer's disease, viral infections, autoimmune disease, and neurodegenerative disorders (no data).


L10 ANSWER 14 OF 5482 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 2002:123000 CAPLUS
 DOCUMENT NUMBER: 136:183709
 TITLE: Novel 1,4-dihydropyridines as bradykinin antagonists
 INVENTOR(S): Ikeda, Takafumi; Kato, Tomoki; Katsui, Yasuhiro;
 Kawai,
 Makoto; Kawamura, Mitsuhiko; Shishido, Yuji; Murase,
 Noriaki
 PATENT ASSIGNEE(S): Pfizer Pharmaceuticals Inc., Japan; Pfizer Inc.
 SOURCE: PCT Int. Appl., 114 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002012235	A1	20020214	WO 2001-181346	20010726
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			


PRIORITY APPLN. INFO.: US 2000-224558P P 20000810

IT 398474-98-1P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (prepn. of bradykinin antagonists 1,4-dihydropyridines via Hantzsch synthesis)
 RN 398474-98-1 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED

L10 ANSWER 14 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)




IT 398474-78-7P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of bradykinin antagonists 1,4-dihydropyridines via Hantzsch synthesis)
 RN 398474-78-7 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED



IT 398475-59-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. of bradykinin antagonists 1,4-dihydropyridines via Hantzsch synthesis)
 RN 398475-59-7 CAPLUS

L10 ANSWER 14 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)
 CN 3,5-Pyridinedicarboxylic acid, 4-(2,6-dichlorophenyl)-1,4-dihydro-2-(2-methoxy-2-oxoethyl)-6-[2-(2-(2-(2-oxo-1-pyrrolidinyl)ethoxy)phenyl)ethyl]-, dimethyl ester (9CI) (CA INDEX NAME)



GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compe. I [wherein each A is independently halo; X = -(CH₂)_m-, -C(O)- or S(O)-; R1 and R2 are independently C1-4 alkyl; R3 is substituted azacycloalkyl etc.; R4 = ortho substituted Ph with substituents selected from substituted C1-7 alkyl, substituted C1-7 alkyl, substituted C1-7 alkoxy, amine, etc; R5 = hydrogen or C1-4 alkyl; m = 0, 1 or 2; and n = 0, 1, 2, 3, 4 or 5] are prepd. and disclosed as bradykinin antagonists. Thus, I was prepd. in seven steps via a modified Hantzsch synthesis involving the cyclocondensation of an intermediate benzylidene with an enamine to create the 1,4-dihydropyridine structural unit. The biol. activity of I was detd. by their ability to inhibit the binding of bradykinin at its receptor sites in recombinant human bradykinin B2 receptor expressing CHO-K1 cells (IC₅₀ values for prepd. compe. ranged from 0.1 nM to 21 nM). The present invention also relates to pharmaceutical compe. contg. such compe. and to the use of such compe. in the treatment and prevention of inflammation, asthma, allergic rhinitis, pain and other disorders.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE


FORMAT

L10 ANSWER 15 OF 5482 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 2002:122980 CAPLUS
 DOCUMENT NUMBER: 136:183708
 TITLE: Preparation of non-imidazole aryloxyalkylamines as histamine H3 receptor antagonists
 INVENTOR(S): Apodaca, Richard; Carruthers, Nicholas I.; Dvorak, Curt A.; Rudolph, Dale A.; Shah, Chandravan R.; Xiao, Wei
 PATENT ASSIGNEE(S): Ortho McNeil Pharmaceutical Inc., USA
 SOURCE: PCT Int. Appl., 155 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002012214	A2	20020214	WO 2001-US24655	20010806
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2000-223768P P 20000808
 US 2001-922631 A 20010806


IT 398473-81-9P, 1-[4-(3-(Piperidin-1-yl)propoxy)phenyl]piperazine hydrochloride 398473-83-1P 398473-99-9P, 1-[3-(4-Benzyloxyphenoxy)propyl]piperidine 398474-00-5P, 4-[4-(3-(Pyrrolidin-1-yl)propoxy)phenyl]piperazine-1-carboxylic acid tert-butyl ester 398474-01-6P, 4-[4-(3-(Piperidin-1-yl)propoxy)phenyl]piperazine-1-carboxylic acid tert-butyl ester 398474-04-9P, 1-[3-(4-(1H-Pyrrol-2-yl)phenoxy)propyl]piperidine
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug; prepn. of non-imidazole aryloxyalkylamines as histamine-H3 receptor antagonists)
 RN 398473-81-9 CAPLUS
 CN Piperazine, 1-[4-(3-(1-piperidinyl)propoxy)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 398473-83-1 CAPLUS

Kamal Saeed

L10 ANSWER 15 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)
CN Piperazine, 1-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]-, monohydrochloride
(9CI) (CA INDEX NAME)




RN 398473-99-9 CAPLUS
CN Piperidine, 1-[3-[4-(phenylmethoxy)phenoxy]propyl]- (9CI) (CA INDEX NAME)




RN 398474-00-5 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


L10 ANSWER 15 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 398474-01-6 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[4-[3-(1-piperidinyl)propoxy]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 398474-04-9 CAPLUS
CN Piperidine, 1-[3-[4-(1H-pyrrol-2-yl)phenoxy]propyl]- (9CI) (CA INDEX NAME)



IT 398473-15-9P, Methyl [4-[3-(piperidin-1-yl)propoxy]benzyl] (2-pyridin-2-ylethyl)amine 398473-16-0P, Benzyl methyl [4-[3-(piperidin-1-yl)propoxy]benzyl]amine 398473-17-1P, Methyl (1-methylpiperidin-4-yl) [4-[3-(piperidin-1-yl)propoxy]benzyl]amine 398473-18-2P, Ethyl [4-[3-(piperidin-1-yl)propoxy]benzyl] [pyridin-4-yl]methylamine 398473-19-3P, [2-(3,4-Dimethoxyphenyl)ethyl] methyl [4-[3-(piperidin-1-yl)propoxy]benzyl]amine 398473-20-6P, Methyl phenethyl [4-[3-(piperidin-1-


L10 ANSWER 15 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)
1-yl)propoxy]benzyl]amine 398473-21-7P, Dimethyl [4-[3-(piperidin-1-yl)propoxy]benzyl]amine 398473-22-8P, Dimethyl [2-[4-(3-(piperidin-1-yl)propoxy)phenoxy]ethyl]amine 398473-23-9P, Methyl phenethyl [3-(3-(piperidin-1-yl)propoxy)benzyl]amine 398473-24-0P, Dibenzyl [3-[2-[4-(3-(piperidin-1-yl)propoxy)phenyl]pyrrol-1-yl]propyl]amine 398473-25-1P, (Indan-1-yl) [4-(3-(piperidin-1-yl)propoxy)benzyl]amine 398473-26-2P, Cyclohexyl [4-(3-(piperidin-1-yl)propoxy)benzyl]amine 398473-27-3P, Cyclopropyl [4-(3-(piperidin-1-yl)propoxy)benzyl]amine 398473-28-4P, Pyridin-2-yl [4-(3-(pyrrolidin-1-yl)propoxy)benzyl]amine 398473-29-5P, [4-(3-(piperidin-1-yl)propoxy)benzyl] [pyridin-2-yl]amine 398473-30-6P, Phenyl [4-(3-(piperidin-1-yl)propoxy)benzyl]amine 398473-31-7P, [3-(3-(piperidin-1-yl)propoxy)benzyl] [pyridin-2-yl]amine 398473-32-0P, (4-Chlorophenyl) [4-(3-(piperidin-1-yl)propoxy)benzyl]amine 398473-33-1P, 4-[3-(3-((piperidin-1-yl)methyl)phenoxy)propyl]morpholine 398473-34-2P, 1-[3-(4-((piperidin-1-yl)methyl)phenoxy)propyl]piperidine 398473-35-3P, Benzyl methyl [1-[4-(3-(piperidin-1-yl)propoxy)benzyl]piperidin-4-yl]amine 398473-36-4P 398473-37-5P, 1-[3-[4-[5-(3-(piperidin-1-yl)propyl)sulfanyl]tetrazol-1-yl]phenoxy]propyl]piperidine 398473-38-6P, 1-[4-(3-(piperidin-1-yl)propoxy)benzyl]piperidin-4-ol 398473-39-7P, 4-[4-(3-(piperidin-1-yl)propoxy)benzyl]morpholine 398473-40-0P, 2-[4-(3-(piperidin-1-yl)propoxy)benzyl]-1,2,3,4-tetrahydroisoquinoline 398473-41-1P, 1-[4-(3-(piperidin-1-yl)propoxy)benzyl]piperidin-4-yl] (pyridin-2-yl)amine 398473-42-2P, 1-Benzyl-4-[4-(3-(piperidin-1-yl)propoxy)benzyl]piperazine 398473-43-3P, 8-[4-(3-(piperidin-1-yl)propoxy)benzyl]-1,4-dioxo-8-azaspiro[4.5]decane 398473-44-4P, 1-[4-(3-(piperidin-1-yl)propoxy)benzyl]piperidine-4-carboxylic acid amide 398473-45-5P, 4-Phenyl-1-[4-(3-(piperidin-1-yl)propoxy)benzyl]piperidin-4-ol 398473-46-6P, 1-Phenyl-4-[4-(3-(piperidin-1-yl)propoxy)benzyl]piperazine 398473-47-7P, Methyl phenethyl [1-[4-(3-(piperidin-1-yl)propoxy)benzyl]piperidin-4-yl]amine 398473-48-8P, 2-Methyl-1-[3-(4-(piperidin-1-yl)methyl)phenoxy]propyl]piperidine 398473-49-9P, 1-[4-(3-(piperidin-1-yl)propoxy)benzyl]piperidin-4-yl] pyridin-2-yl (2-(pyrrolidin-1-yl)methyl)phenoxy]propyl]piperidine 398473-51-3P, 1-[3-(4-(pyrrolidin-1-yl)methyl)phenoxy]propyl]piperidine 398473-52-4P, 1-[3-[4-(4-benzylidenepiperidin-1-yl)methyl]phenoxy]propyl]piperidine 398473-53-5P, 1-[3-(4-((4-benzylpiperidin-1-yl)methyl)phenoxy)propyl]piperidine 398473-54-6P, 2-(4-Chlorophenyl)-5-[4-(3-(piperidin-1-yl)propoxy)benzyl]-2,5-diazabicyclo[2.2.1]heptane 398473-55-7P, 1-[3-(2'-((piperidin-1-yl)methyl)biphenyl-4-yl)oxy]propyl]piperidine 398473-56-8P, 1-[1-[4-(3-(piperidin-1-yl)propoxy)benzyl]piperidin-4-yl]-1,3-dihydrobenzimidazol-2-one 398473-57-9P, 1-[3-[4-[1-(3-(piperidin-1-yl)propyl)-1H-pyrrol-2-yl]phenoxy]propyl]piperidine 398473-58-0P, 1-[3-phenylpropen-2-yl]-4-[4-(3-(piperidin-1-yl)propoxy)benzyl]piperazine 398473-59-1P 1-[3-(3-((4-(benzylidene)piperidin-1-yl)methyl)phenoxy)propyl]piperidine 398473-60-4P, 4-(4-Chlorophenyl)-1-[4-(3-(piperidin-1-yl)propoxy)benzyl]piperidin-4-ol 398473-61-5P, 1-[4-(3-(piperidin-1-yl)propoxy)benzyl]piperidin-4-ol 398473-62-6P, 1-[1-[4-(3-(piperidin-1-yl)propoxy)benzyl]piperidin-4-yl]-1H-benzimidazole 398473-63-7P 398473-64-8P,

Kamal Saeed


L10 ANSWER 15 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)
1-[1-[4-(3-(piperidin-1-yl)propoxy)benzyl]piperidin-4-yl]-2,3-dihydro-1H-indole 398473-65-9P, 1-Isopropyl-4-[4-(3-(piperidin-1-yl)propoxy)benzyl]piperazine 398473-66-0P, 1-[4-(3-(piperidin-1-yl)propoxy)benzyl]azacyclotridecane 398473-67-1P, 1-Methyl-4-[4-(3-(piperidin-1-yl)propoxy)benzyl]piperazine 398473-68-2P, 5-Bromo-1-[1-[4-(3-(piperidin-1-yl)propoxy)benzyl]piperidin-4-yl]-2,3-dihydro-1H-indole 398473-69-3P, 2-[1-[3-(4-((piperidin-1-yl)methyl)phenoxy)propyl]piperidin-2-yl]ethanol 398473-70-6P, 4-[3-(4-((piperidin-1-yl)methyl)phenoxy)propyl]morpholine 398473-71-7P, 2-[4-(2-(piperidin-1-yl)ethoxy)benzyl]-1,2,3,4-tetrahydroisoquinoline 398473-72-8P, 1-[4-(3-(piperidin-1-yl)propoxy)benzyl]-1,2,3,4-tetrahydroquinoline 398473-73-9P, 1-[2-(4-((piperidin-1-yl)methyl)phenoxy)ethyl]piperidine 398473-75-1P, 5-(3-(piperidin-1-yl)propoxy)-2-[4-(3-(piperidin-1-yl)propoxy)phenyl]pyrimidine 398473-76-2P, 1-Methyl-4-[3-(4-((piperidin-1-yl)methyl)phenoxy)propyl]piperazine 398473-77-3P, 1-[4-(2-(piperidin-1-yl)ethoxy)benzyl]-1,2,3,4-tetrahydroquinoline 398473-78-4P, (4-Chlorophenyl) [3-(3-(piperidin-1-yl)propoxy)benzyl]amine 398473-79-5P, 1-Benzyl-4-[4-(3-(piperidin-1-yl)propoxy)phenyl]piperidin-4-ol 398473-80-8P, 1-Isopropyl-4-[4-(3-(piperidin-1-yl)propoxy)phenyl]piperazine 398473-82-0P, 1-Benzyl-4-[4-(3-(pyrrolidin-1-yl)propoxy)phenyl]piperazine 398473-84-2P, 1-[4-(3-(piperidin-1-yl)propoxy)phenyl]piperazine 398473-85-3P, 1-[4-(3-(pyrrolidin-1-yl)propoxy)phenyl]piperazine 398473-86-4P, 1-[3-[2'-(1-Isopropyl)piperidin-4-yl]biphenyl-4-yl]oxy]propyl]piperidine 398473-87-5P, 1-[3-[4-(2-(1-Methylpyrrolidin-2-yl)ethyl)phenoxy]propyl]piperidine 398473-88-6P, 1-[3-(4-((1-Isopropyl)piperidin-4-yl)methyl)phenoxy]propyl]piperidine 398473-89-7P, 1-[3-[4-(1-Methylpyrrolidin-2-yl)phenoxy]propyl]piperidine 398473-90-0P, 1-Isopropyl-4-[4-(3-(piperidin-1-yl)propoxy)phenyl]piperidin-4-ol 398473-91-1P, [3-(Puran-2-yl)-3-[4-(3-(piperidin-1-yl)propoxy)phenyl]propyl]dimethylamine 398473-92-2P, 4-[3-[4-(3-(piperidin-1-yl)propoxy)phenyl]-3-(pyrimidin-2-yl)propyl]morpholine 398473-93-3P, 4-[4,4,4-Trifluoro-3-[4-(3-(piperidin-1-yl)propoxy)phenyl]butyl]morpholine 398473-94-4P, (2-(Morpholin-4-yl)ethyl) [4-(3-(piperidin-1-yl)propoxy)phenyl] (pyridin-2-yl)amine 398473-95-5P, Isopropyl (2-morpholin-4-ylethyl) [4-(3-(piperidin-1-yl)propoxy)phenyl]amine 398473-96-6P, (2-(Morpholin-4-ylethyl) [4-(3-(piperidin-1-yl)propoxy)phenyl] (thiazol-2-yl)methyl]amine 398474-05-0P, 4-[3-(3-((piperidin-1-yl)methyl)phenoxy)propyl]morpholine dihydrochloride 398474-06-1P, 1-[3-[4-(2-(piperidin-1-yl)ethoxy)phenoxy]propyl]piperidine 398474-07-2P, 1-[3-[4-(3-(piperidin-1-yl)propoxy)phenoxy]propyl]piperidine 398474-12-9P, (2-(3-(piperidin-1-yl)propoxy)benzyl] (pyridin-2-yl)amine 398474-13-0P, (4-Chlorophenyl) [2-(3-(piperidin-1-yl)propoxy)benzyl]amine 398474-14-1P, 1-[3-[4-(4-(benzylidene)piperidin-1-yl)methyl]phenoxy]propyl]piperidine RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (drug; prepn. of non-imidazole aryloxyalkylamines as histamine-H3 receptor antagonists)

RN 398473-15-9 CAPLUS


L10 ANSWER 15 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)
 CN 2-Pyridineethanamine,
 N-methyl-N-[[4-[3-(1-piperidinyl)propoxy]phenyl]meth
 yl]- (9CI) (CA INDEX NAME)




RN 398473-16-0 CAPLUS
 CN Benzenemethanamine,
 N-methyl-N-(phenylmethyl)-4-[3-(1-piperidinyl)propoxy]-
 (9CI) (CA INDEX NAME)



RN 398473-17-1 CAPLUS
 CN 4-Piperidinamine,
 N,1-dimethyl-N-[[4-[3-(1-piperidinyl)propoxy]phenyl]meth
 yl]- (9CI) (CA INDEX NAME)




RN 398473-18-2 CAPLUS
 CN 4-Pyridinemethanamine,
 N-ethyl-N-[[4-[3-(1-piperidinyl)propoxy]phenyl]meth
 yl]- (9CI) (CA INDEX NAME)




RN 398473-19-3 CAPLUS
 CN Benzenethanamine, 3,4-dimethoxy-N-methyl-N-[[4-[3-(1-
 piperidinyl)propoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)


L10 ANSWER 15 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 398473-24-0 CAPLUS
 CN 1H-Pyrrole-1-propanamine, N,N-bis(phenylmethyl)-2-[4-[3-(1-
 piperidinyl)propoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 398473-25-1 CAPLUS
 CN 1H-Inden-1-amine,
 2,3-dihydro-N-[[4-[3-(1-piperidinyl)propoxy]phenyl]meth
 yl]- (9CI) (CA INDEX NAME)




RN 398473-26-2 CAPLUS
 CN Benzenemethanamine, N-cyclohexyl-4-[3-(1-piperidinyl)propoxy]- (9CI) (CA
 INDEX NAME)




RN 398473-27-3 CAPLUS
 CN Benzenemethanamine, N-cyclopropyl-4-[3-(1-piperidinyl)propoxy]- (9CI)
 (CA INDEX NAME)


L10 ANSWER 15 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 398473-20-6 CAPLUS
 CN Benzenethanamine,
 N-methyl-N-[[4-[3-(1-piperidinyl)propoxy]phenyl]methyl]-
 (9CI) (CA INDEX NAME)



RN 398473-21-7 CAPLUS
 CN Benzenemethanamine, N,N-dimethyl-4-[3-(1-piperidinyl)propoxy]- (9CI) (CA
 INDEX NAME)




RN 398473-22-8 CAPLUS
 CN Ethanamine, N,N-dimethyl-2-[4-[3-(1-piperidinyl)propoxy]phenoxy]- (9CI)
 (CA INDEX NAME)




RN 398473-23-9 CAPLUS
 CN Benzenethanamine,
 N-methyl-N-[[3-[3-(1-piperidinyl)propoxy]phenyl]methyl]-
 (9CI) (CA INDEX NAME)


L10 ANSWER 15 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 398473-28-4 CAPLUS
 CN 2-Pyridinamine, N-[[4-[3-(1-pyrrolidinyl)propoxy]phenyl]methyl]- (9CI)
 (CA INDEX NAME)




RN 398473-29-5 CAPLUS
 CN 2-Pyridinamine, N-[[4-[3-(1-piperidinyl)propoxy]phenyl]methyl]- (9CI)
 (CA INDEX NAME)




RN 398473-30-8 CAPLUS
 CN Benzenemethanamine, N-phenyl-4-[3-(1-piperidinyl)propoxy]- (9CI) (CA
 INDEX NAME)




L10 ANSWER 15 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)
 RN 398473-31-9 CAPLUS
 CN 2-Pyridinamine, N-[[3-[3-(1-piperidinyl)propoxy]phenyl]methyl]- (9CI)
 (CA INDEX NAME)




RN 398473-32-0 CAPLUS
 CN Benzenemethanamine, N-(4-chlorophenyl)-4-[3-(1-piperidinyl)propoxy]- (9CI)
 (CA INDEX NAME)



RN 398473-33-1 CAPLUS
 CN Morpholine, 4-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]- (9CI) (CA INDEX NAME)




RN 398473-34-2 CAPLUS
 CN Piperidine, 1-[3-[4-(1-piperidinylmethyl)phenoxy]propyl]- (9CI) (CA INDEX NAME)




RN 398473-35-3 CAPLUS
 CN 4-Piperidinamine, N-methyl-N-(phenylmethyl)-1-[[4-[3-(1-piperidinyl)propoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




L10 ANSWER 15 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)
 CN Morpholine, 4-[[4-[3-(1-piperidinyl)propoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 398473-40-0 CAPLUS
 CN Isoquinoline, 1,2,3,4-tetrahydro-2-[[4-[3-(1-piperidinyl)propoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 398473-41-1 CAPLUS
 CN 2-Pyridinamine, N-[1-[[4-[3-(1-piperidinyl)propoxy]phenyl]methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 398473-42-2 CAPLUS
 CN Piperazine, 1-(phenylmethyl)-4-[[4-[3-(1-piperidinyl)propoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 398473-43-3 CAPLUS
 CN 1,4-Dioxo-8-azaspiro[4.5]decane, 6-[[4-[3-(1-piperidinyl)propoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




L10 ANSWER 15 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 398473-36-4 CAPLUS
 CN Piperidine-2,2,3,3,4,4,5,5,6,6-d10, 1-[3-[4-(1-piperidinylmethyl)phenoxy]propyl]- (9CI) (CA INDEX NAME)



RN 398473-37-5 CAPLUS
 CN Piperidine, 1-[3-[[1-[4-[3-(1-piperidinyl)propoxy]phenyl]-1H-tetrazol-5-yl]thio]propyl]- (9CI) (CA INDEX NAME)




RN 398473-38-6 CAPLUS
 CN 4-Piperidinol, 1-[[4-[3-(1-piperidinyl)propoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 398473-39-7 CAPLUS


L10 ANSWER 15 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 398473-44-4 CAPLUS
 CN 4-Piperidinecarboxamide, 1-[[4-[3-(1-piperidinyl)propoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 398473-45-5 CAPLUS
 CN 4-Piperidinol, 4-phenyl-1-[[4-[3-(1-piperidinyl)propoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 398473-46-6 CAPLUS
 CN Piperazine, 1-phenyl-4-[[4-[3-(1-piperidinyl)propoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 398473-47-7 CAPLUS
 CN 4-Piperidinamine, N-methyl-N-(2-phenylethyl)-1-[[4-[3-(1-piperidinyl)propoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)







RN 398473-48-8 CAPLUS
CN Piperidine, 2-methyl-1-[3-[4-(1-piperidinylmethyl)phenoxy]propyl]-4-piperidinylmethyl-phenylmethanol (9CI) (CA INDEX NAME)




RN 398473-49-9 CAPLUS
CN 2-Pyridinamine, N-[1-[4-[3-(1-piperidinyl)propoxy]phenyl]methyl]-4-piperidinyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)


PAGE 1-A




RN 398473-53-5 CAPLUS
CN Piperidine, 1-[3-[2-[4-[3-(1-piperidinyl)propoxy]phenyl]methyl]-4-(phenylmethyl)-1-[[4-[3-(1-piperidinyl)propoxy]phenyl]methyl]-1-phenyl]- (9CI) (CA INDEX NAME)



RN 398473-54-6 CAPLUS
CN 2,5-Diazabicyclo[2.2.1]heptane, 2-(4-chlorophenyl)-5-[[4-[3-(1-piperidinyl)propoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 398473-55-7 CAPLUS
CN Piperidine, 1-[3-[2-[4-[3-(1-piperidinyl)propoxy]phenyl]methyl]-4-(phenylmethyl)-1-[[4-[3-(1-piperidinyl)propoxy]phenyl]methyl]-1-phenyl]- (9CI) (CA INDEX NAME)




RN 398473-56-8 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1-[[4-[3-(1-piperidinyl)propoxy]phenyl]methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)


PAGE 2-A




RN 398473-50-2 CAPLUS
CN 4-Piperidineethanol, 1-[[4-[3-(1-piperidinyl)propoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 398473-51-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 398473-52-4 CAPLUS
CN Piperidine, 4-(phenylmethylene)-1-[[4-[3-(1-piperidinyl)propoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 398473-57-9 CAPLUS
CN Piperidine, 1-[3-[2-[4-[3-(1-piperidinyl)propoxy]phenyl]-1H-pyrrol-1-yl]propyl]- (9CI) (CA INDEX NAME)



RN 398473-58-0 CAPLUS
CN Piperazine, 1-(3-phenyl-2-propenyl)-4-[[4-[3-(1-piperidinyl)propoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 398473-59-1 CAPLUS
CN Piperidine, 4-(phenylmethylene)-1-[[3-[3-(1-piperidinyl)propoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 398473-60-4 CAPLUS
CN 4-Piperidinol, 4-(4-chlorophenyl)-1-[[4-[3-(1-piperidinyl)propoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)


L10 ANSWER 15 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 398473-61-5 CAPLUS
CN Piperidine,
4-(3-phenylpropyl)-1-[[4-[3-(1-piperidinyl)propoxy]phenyl]meth
yl]- (9CI) (CA INDEX NAME)



RN 398473-62-6 CAPLUS
CN 1H-Benzimidazole, 1-[[4-[3-(1-piperidinyl)propoxy]phenyl]methyl]-4-
piperidinyl- (9CI) (CA INDEX NAME)




RN 398473-63-7 CAPLUS
CN Pyridine,
3-[[4-[3-(1-piperidinyl)propoxy]phenyl]methyl]-2-piperidinyl]-
(9CI) (CA INDEX NAME)




RN 398473-64-8 CAPLUS
CN 1H-Indole,
2,3-dihydro-1-[[4-[3-(1-piperidinyl)propoxy]phenyl]methyl]-4-
piperidinyl]- (9CI) (CA INDEX NAME)


L10 ANSWER 15 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 398473-68-2 CAPLUS
CN 1H-Indole, 5-bromo-2,3-dihydro-1-[[4-[3-(1-
piperidinyl)propoxy]phenyl]methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 398473-69-3 CAPLUS
CN 2-Piperidineethanol, 1-[3-[4-(1-piperidinylmethyl)phenoxy]propyl]- (9CI)
(CA INDEX NAME)




RN 398473-70-6 CAPLUS
CN Morpholine, 4-[3-[4-(1-piperidinylmethyl)phenoxy]propyl]- (9CI) (CA
INDEX NAME)




RN 398473-71-7 CAPLUS
CN Isoquinoline,
1,2,3,4-tetrahydro-2-[[4-[2-(1-piperidinyl)ethoxy]phenyl]met
hyl]- (9CI) (CA INDEX NAME)


L10 ANSWER 15 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 398473-65-9 CAPLUS
CN Piperazine,
1-(1-methylethyl)-4-[[4-[3-(1-piperidinyl)propoxy]phenyl]meth
yl]- (9CI) (CA INDEX NAME)




RN 398473-66-0 CAPLUS
CN Azacyclotridecane, 1-[[4-[3-(1-piperidinyl)propoxy]phenyl]methyl]- (9CI)
(CA INDEX NAME)




RN 398473-67-1 CAPLUS
CN Piperazine, 1-methyl-4-[[4-[3-(1-piperidinyl)propoxy]phenyl]methyl]-
(9CI) (CA INDEX NAME)


L10 ANSWER 15 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 398473-72-8 CAPLUS
CN Quinoline,
1,2,3,4-tetrahydro-1-[[4-[3-(1-piperidinyl)propoxy]phenyl]meth
yl]- (9CI) (CA INDEX NAME)



RN 398473-73-9 CAPLUS
CN Piperidine, 1-[[4-[2-(1-piperidinyl)ethoxy]phenyl]methyl]- (9CI) (CA
INDEX NAME)




RN 398473-75-1 CAPLUS
CN Pyrimidine, 5-[3-(1-piperidinyl)propoxy]-2-[4-[3-(1-
piperidinyl)propoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 398473-76-2 CAPLUS


L10 ANSWER 15 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)
 CN Piperazine, 1-methyl-4-[3-[4-(1-piperidinylmethyl)phenoxy]propyl]- (9CI)
 (CA INDEX NAME)



RN 398473-77-3 CAPLUS
 CN Quinoline,
 1,2,3,4-tetrahydro-1-[[4-[2-(1-piperidinyl)ethoxy]phenyl]methyl]-
]- (9CI) (CA INDEX NAME)




RN 398473-78-4 CAPLUS
 CN Benzenemethanamine, N-(4-chlorophenyl)-3-[3-(1-piperidinyl)propoxy]-
 (9CI) (CA INDEX NAME)




RN 398473-79-5 CAPLUS
 CN 4-Piperidinol, 1-(phenylmethyl)-4-[4-[3-(1-piperidinyl)propoxy]phenyl]-


L10 ANSWER 15 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)
 (9CI) (CA INDEX NAME)



RN 398473-80-8 CAPLUS
 CN Piperazine, 1-(1-methylethyl)-4-[4-[3-(1-piperidinyl)propoxy]phenyl]-
 (9CI) (CA INDEX NAME)




RN 398473-82-0 CAPLUS
 CN Piperazine, 1-(phenylmethyl)-4-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]-
 (9CI) (CA INDEX NAME)




RN 398473-84-2 CAPLUS
 CN Piperazine, 1-[4-[3-(1-piperidinyl)propoxy]phenyl]- (9CI) (CA INDEX NAME)


L10 ANSWER 15 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 398473-85-3 CAPLUS
 CN Piperazine, 1-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 398473-86-4 CAPLUS
 CN Piperidine, 1-(1-methylethyl)-4-[4'-[3-(1-piperidinyl)propoxy][1,1'-
 biphenyl]-2-yl]- (9CI) (CA INDEX NAME)




RN 398473-87-5 CAPLUS
 CN Piperidine, 1-[3-[4-[2-(1-methyl-2-pyrrolidinyl)ethyl]phenoxy]propyl]-
 (9CI) (CA INDEX NAME)


L10 ANSWER 15 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 398473-88-6 CAPLUS
 CN Piperidine, 1-(1-methylethyl)-4-[4-[3-(1-piperidinyl)propoxy]phenyl]methyl-
 1]- (9CI) (CA INDEX NAME)




RN 398473-89-7 CAPLUS
 CN Piperidine, 1-[3-[4-(1-methyl-2-pyrrolidinyl)phenoxy]propyl]- (9CI) (CA INDEX NAME)




RN 398473-90-0 CAPLUS
 CN Piperidine, 1-(1-methylethyl)-4-[4-[3-(1-piperidinyl)propoxy]phenyl]-
 (9CI) (CA INDEX NAME)




RN 398473-91-1 CAPLUS
 CN 2-Furanpropanamine, N,N-dimethyl-.gamma.-[4-[3-(1-piperidinyl)propoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 398473-92-2 CAPLUS
CN Morpholine, 4-([3-([3-(1-piperidinyl)propoxy]phenyl)-2-pyrimidinyl]propyl)- (9CI) (CA INDEX NAME)



RN 398473-93-3 CAPLUS
CN Morpholine,
4-([4,4,4-trifluoro-3-([3-(1-piperidinyl)propoxy]phenyl)butyl]- (9CI) (CA INDEX NAME)




RN 398473-94-4 CAPLUS
CN 4-Morpholineethanamine, N-[4-([3-(1-piperidinyl)propoxy]phenyl)-N-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 398473-95-5 CAPLUS
CN 4-Morpholineethanamine, N-(1-methylethyl)-N-[4-([3-(1-piperidinyl)propoxy]phenyl)- (9CI) (CA INDEX NAME)


RN 398474-07-2 CAPLUS
CN Piperidine, 1,1'-([1,4-phenylenebis(oxy-3,1-propanediyl)]bis- (9CI) (CA INDEX NAME)




RN 398474-12-9 CAPLUS
CN 2-Pyridinamine, N-[[2-([3-(1-piperidinyl)propoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 398474-13-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 398474-14-1 CAPLUS
CN Piperidine,
4-(phenylmethylene)-1-[[2-([3-(1-piperidinyl)propoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




Kamal Saeed



RN 398473-96-6 CAPLUS
CN 4-Morpholineethanamine, N-[4-([3-(1-piperidinyl)propoxy]phenyl)-N-(2-thiazolylmethyl)- (9CI) (CA INDEX NAME)




RN 398474-05-0 CAPLUS
CN Morpholine, 4-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl


RN 398474-06-1 CAPLUS
CN Piperidine, 1-[3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]propyl]- (9CI) (CA INDEX NAME)




81878-15-1P, 4-(3-(1-piperidinyl)propoxy)phenol
82625-43-2P, 3-(3-(1-piperidinyl)propoxy)benzaldehyde
82625-46-5P, 4-(3-(1-piperidinyl)propoxy)benzaldehyde
398473-98-8P, 1-[3-(4-iodophenoxy)propyl]piperidine
398474-03-8P, 4'-[3-(1-piperidinyl)propoxy]biphenyl-2-carboxaldehyde
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of non-imidazole aryloxyalkylamines as histamine-H3 receptor antagonists)
RN 68997-50-2 CAPLUS
CN Benzaldehyde, 2-[3-(1-piperidinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 81878-15-1 CAPLUS
CN Phenol, 4-[3-(1-piperidinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 82625-43-2 CAPLUS
CN Benzaldehyde, 3-[3-(1-piperidinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 82625-46-5 CAPLUS
CN Benzaldehyde, 4-[3-(1-piperidinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 398473-98-8 CAPLUS
CN Piperidine, 1-[3-(4-iodophenoxy)propyl]- (9CI) (CA INDEX NAME)




RN 398474-03-8 CAPLUS
CN [1,1'-Biphenyl]-2-carboxaldehyde, 4'-[3-(1-piperidinyl)propoxy]- (9CI)
(CA INDEX NAME)




IT	164917-35-5, 4-[3-(1-pyrrolidin-1-yl)propoxy]benzaldehyde
RL:	RCT (Reactant); RACT (Reactant or reagent)
	(reactant; prepn. of non-imidazole aryloxyalkylamines as histamine-H3 receptor antagonists)
RN	164917-35-5 CAPLUS
CN	Benzaldehyde, 4-[3-(1-pyrrolidinyl)propoxy]- (9CI) (CA INDEX NAME)



GI



I



11

AB Title compds. I [Ra-b = alk(en/yn)yl, cycloalkyl; n = 0-4; one of R1-3 =
G


and the remaining two are H or halo; G = N-contg. heterocycle, e.g., piperidinyl, etc.] were prepd. For instance, 4-(2-(piperidin-1-yl)ethoxy)benzaldehyde was used to alkylate

1,2,3,4-tetrahydroisquinoline (ClCH₂CH₂Cl, HOAc, NaBH(OAc)₃, 15 h) to give II. II had K_i = 37 nM for the histamine H₃ receptor. I are useful for treating histamine-mediated conditions.

ACCESSION NUMBER: 2002.122971 CRPLUS
DOCUMENT NUMBER: 136.185440
TITLE: Benzotriazoles containing .alpha.-cumyl groups substituted by heteroatoms and stable compositions
INVENTOR(S): Wood, Mervin Gale; Suhadolnik, Joseph; Ravichandran, Ramathan; Lau, Jacqueline; Hendricks-Guy, Carmen; Bulliard, Christophe
PATENT ASSIGNEE(S): Ciba Specialty Chemicals Holding Inc., Switz.
SOURCE: PCT Int. Appl., 92 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002012205	A1	20020214	WO 2001-EP8665	20010726
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DP, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, IL, IN, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MG, MK, MN, MX, MY, MZ, NO, NZ, PL, PT, RU, RO, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW	AG, BG, BR, BY, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DP, EE, EG, ES, FI, FR, GB, GR, IE, IT, LJ, MK, MR, NE, NL, PT, SE, TR, CF, BJ, CG, CI, CM, GA, GN, GU, GW, ML, MR, NE, SN, TD, TG	2001-EP8665	20010726
RW: GH, GM, KE, LS, LU, MG, MW, MZ, SD, SL, ST, SZ, TH, TN, TZ, UG, ZW				
RW: DE, DK, ES, FI, FR, GB, GR, IE, IT, LJ, MK, MR, NE, NL, PT, SE, TR, CF, BJ, CG, CI, CM, GA, GN, GU, GW, ML, MR, NE, SN, TD, TG			US 2000-632216	
PRIORITY APPLN. INFO.:			A 20000803	

PRIORITY APPLN. INFO.: US 2000-632216 A 20000803
IT 398474-56-1P
RL: IMF (Industrial manufacture); MOA (Modifier or additive use); PREP
(Preparation); USES (Use)
(benzotriazoles contg. .alpha.-cumyl groups substituted by heteroatoms
and stable compns.)
RN 398474-56-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



AB 2H-Benzotriazole UV absorbers substituted at the 3-position end/or the 5-position of the UV absorber by alpha-cumyl moiety which is substituted by a heteroatom are particularly photostable in automotive protective photocopy layers, and are of low color and exhibit low volatility in thermoplastic compns. Automotive coatings of a melamine-curable acrylic polyol binder stabilized using benzotriazole UV absorber.

Kamal Saeed


L10 ANSWER 17 OF 5482 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 2002:122958 CAPLUS
 DOCUMENT NUMBER: 136:167286
 TITLE: Preparation of cyclic amine derivatives as remedies for obesity and diabetes
 INVENTOR(S): Yano, Toshiasada; Sakaguchi, Isako; Katsura, Goro;
 PATENT ASSIGNEE(S): Yoshikawa, Naoki
 SOURCE: Shionogi & Co., Ltd., Japan
 PCT Int. Appl., 51 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002012191	A1	20020214	WO 2001-JP6673	20010802


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLW. INFO.: JP 2000-239647 A 20000808
 OTHER SOURCE(S): MARPAT 136:167286
 IT 398126-32-4P 398126-34-6P 398126-35-7P
 398126-36-8P 398126-37-9P 398126-39-1P
 398126-41-5P 398126-43-7P 398126-44-8P
 398126-45-9P 398126-46-0P 398126-47-1P
 398126-48-2P 398126-49-3P 398126-50-4P
 398126-51-7P 398126-52-8P 398126-53-9P
 398126-54-0P 398126-55-1P 398126-56-2P
 398126-57-3P 398126-58-4P 398126-59-5P
 398126-60-8P 398126-61-9P 398126-64-2P
 398126-65-3P 398126-66-4P 398126-67-5P
 398126-68-6P 398126-69-7P 398126-70-0P
 398126-71-1P 398126-72-2P 398126-73-3P
 398126-74-4P 398126-75-5P 398126-76-6P
 398126-77-7P 398126-78-8P 398126-79-9P
 398126-80-2P 398126-81-3P 398126-82-4P
 398126-83-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of cyclic amine derivs. as remedies for obesity and diabetes)
 RN 398126-32-4 CAPLUS
 CN Pyridine,
 1,2,3,6-tetrahydro-1-[3-[4-[[4-(trifluoromethyl)phenyl]methyl]phenoxy]propyl]-, ethanediolate (1:1) (9CI) (CA INDEX NAME)
 CM 1
 CRN 398126-31-3
 CMP C22 H24 F3 N O


L10 ANSWER 17 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 398126-37-9 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 398126-39-1 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED



● HCl


RN 398126-41-5 CAPLUS
 CN Pyridine, 2-[[4-[3-(3,6-dihydro-1(2H)-pyridinyl)propoxy]phenyl]thio]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 398126-43-7 CAPLUS
 CN Pyridine, 2-[[4-[3-(3,6-dihydro-1(2H)-pyridinyl)propoxy]phenyl]thio]-5-(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Kamal Saeed

L10 ANSWER 17 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)




CM 2


CRN 144-62-7
 CMP C2 H2 O4



RN 398126-34-6 CAPLUS
 CN Benzenamine, N-[4-[3-(3,6-dihydro-1(2H)-pyridinyl)propoxy]phenyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 398126-35-7 CAPLUS
 CN Pyridine,
 1,2,3,6-tetrahydro-1-[3-[4-[[4-(trifluoromethyl)phenyl]thio]phenoxy]propyl]- (9CI) (CA INDEX NAME)




RN 398126-36-8 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED

L10 ANSWER 17 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)




● HCl

RN 398126-44-8 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 398126-45-9 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED



● HCl


RN 398126-46-0 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED



RN 398126-47-1 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED

L10 ANSWER 17 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)
CM 1

CRN 398126-46-0
CMP C21 H23 F3 N2 O4 S




CM 2

CRN 144-62-7
CMP C2 H2 O4




RN 398126-48-2 CAPLUS
CN Pyridine,
1,2,3,6-tetrahydro-1-[4-[4-[(trifluoromethyl)phenyl]thio]phenoxy]butyl]- (9CI) (CA INDEX NAME)



RN 398126-49-3 CAPLUS
CN Pyridine,
1,2,3,6-tetrahydro-1-[4-[4-[(trifluoromethyl)phenyl]thio]phenoxy]butyl]-, hydrochloride (9CI) (CA INDEX NAME)


L10 ANSWER 17 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)

RN 398126-53-9 CAPLUS
CN Pyridine, 2-[[4-[4-(3,6-dihydro-1(2H)-pyridinyl)butoxy]phenyl]thio]-5-(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 398126-54-0 CAPLUS
CN Pyridine,
1,2,3,6-tetrahydro-1-[4-[4-[(trifluoromethoxy)phenyl]thio]phenoxy]butyl]- (9CI) (CA INDEX NAME)



RN 398126-55-1 CAPLUS
CN Pyridine,
1,2,3,6-tetrahydro-1-[4-[4-[(trifluoromethoxy)phenyl]thio]phenoxy]butyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 398126-54-0
CMP C22 H24 F3 N O2 S




CM 2

CRN 144-62-7
CMP C2 H2 O4


Kamal Saeed

L10 ANSWER 17 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)




● HCl

RN 398126-50-6 CAPLUS
CN Pyridine,
1,2,3,6-tetrahydro-1-[4-[4-[(trifluoromethyl)phenyl]methyl]phenoxy]butyl]- (9CI) (CA INDEX NAME)




RN 398126-51-7 CAPLUS
CN Pyridine,
1,2,3,6-tetrahydro-1-[4-[4-[(trifluoromethyl)phenyl]methyl]phenoxy]butyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 398126-52-8 CAPLUS
CN Pyridine, 2-[[4-[4-(3,6-dihydro-1(2H)-pyridinyl)butoxy]phenyl]thio]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




L10 ANSWER 17 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 398126-56-2 CAPLUS
CN Pyridine, 1-[4-[4-[(5-bromo-2-fluorophenyl)thio]phenoxy]butyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)




RN 398126-57-3 CAPLUS
CN Pyridine, 1-[4-[4-[(5-bromo-2-fluorophenyl)thio]phenoxy]butyl]-1,2,3,6-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 398126-58-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 398126-59-5 CAPLUS
CN Benzenesulfonamide,
N-[4-[4-(3,6-dihydro-1(2H)-pyridinyl)butoxy]phenyl]-4-(trifluoromethyl)-, ethanedioate (1:1) (9CI) (CA INDEX NAME)


CRN 398126-58-4
CMF C22 H25 F3 N2 O3 S




CRN 144-62-7
CMP C2 H2 O4



RN 398126-60-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 398126-61-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




● HCl

RN 398126-64-2 CAPLUS


ClC1=CC=C(C=C1)OCCN2CCCCC2

RN 398126-68-6 CAPLUS
CN Pyridine.
1,2,3,6-tetrahydro-1-[4-{3-[4-(trifluoromethyl)phenoxy]phenoxy}b
utyl)-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 398126-69-7 CAPLUS
CN Pyridine,
1,2,3,6-tetrahydro-1-[4-[3-[4-(trifluoromethyl)phenoxy]b
utyl)-(9CI) (CA INDEX NAME)




RN 398126-70-0 CAPLUS
CN Pyridine, 2-[4-[3-(3,6-dihydro-1(2H)-pyridinyl)propoxy]phenoxy]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 398126-71-1 CAPLUS
CN Pyridine, 2-[4-[3-(3,6-dihydro-1(2H)-pyridinyl)propoxy]phenoxy]-5-(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

1,2,3,6-tetrahydro-1-([4-(4-(trifluoromethyl)phenoxy)phenoxy]p
entyl)-(9CI) (CA INDEX NAME)




RN 398126-65-3 CAPLUS
CN Pyridine,
1,2,3,6-tetrahydro-1-[5-(4-[4-(trifluoromethyl)phenoxy]phenoxy)p
entyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 398126-66-4 CAPLUS
CN Pyridine,
1,2,3,6-tetrahydro-1-[6-[4-[4-(trifluoromethyl)phenoxy]phenoxy]h
exyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 398126-67-5 CAPLUS
CN Pyridine,
1,2,3,6-tetrahydro-1-[6-[4-[4-(trifluoromethyl)phenoxy]phenoxy]h
exyl]- (9CI) (CA INDEX NAME)


C1=CC=CC=C1N(C1=CC=CC=C1)CCCC1=CC=CC=C1OC1=CC=C(C=C1)Oc2ccc(C(F)(F)F)cn2

● HCl

RN 398126-72-2 CAPLUS
CN Pyridine,
1,2,3,6-tetrahydro-1-({4-({4-({4-(trifluoromethoxy)phenoxy)
butyl}-(9CI) (CA INDEX NAME)




RN 398126-73-3 CAPLUS
CN Pyridine,
1,2,3,6-tetrahydro-1-[(4-{4-(4-(trifluoromethoxy)phenoxy)phenoxy}
butyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 398126-74-4 CAPLUS
CN Pyridine, 1,2,3,6-tetrahydro-1-[4-(4-(2-pyridinyloxy)phenoxy)butyl]-
(9CI)
(CA INDEX NAME)



L10 ANSWER 17 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)


RN 398126-75-5 CAPLUS
CN Pyridine, 1,2,3,6-tetrahydro-1-[4-[4-(2-pyridinyloxy)phenoxy]butyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)
CM 1
CRN 398126-74-4
CMP C20 H24 N2 O2



CM 2
CRN 144-62-7
CMP C2 H2 O4




RN 398126-76-6 CAPLUS
CN Pyridine, 1-[3-[3-chloro-4-(3,4-difluorophenoxy)phenoxy]propyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)




RN 398126-77-7 CAPLUS
CN Pyridine, 1-[3-[3-chloro-4-(3,4-difluorophenoxy)phenoxy]propyl]-1,2,3,6-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)

L10 ANSWER 17 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 398126-81-3 CAPLUS
CN Pyridine, 2-[4-[4-(3,6-dihydro-1(2H)-pyridinyl)butoxy]phenoxy]-5-(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 398126-82-4 CAPLUS
CN Pyridine, 1,2,3,6-tetrahydro-1-[3-[4-[4-(trifluoromethoxy)phenoxy]phenoxy]propyl]- (9CI) (CA INDEX NAME)




RN 398126-83-5 CAPLUS
CN Pyridine, 1,2,3,6-tetrahydro-1-[3-[4-[4-(trifluoromethoxy)phenoxy]phenoxy]propyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

L10 ANSWER 17 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)




● HCl

RN 398126-78-8 CAPLUS
CN Pyridine, 1-[4-[3-chloro-4-(3,4-difluorophenoxy)phenoxy]butyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 398126-79-9 CAPLUS
CN Pyridine, 1-[4-[3-chloro-4-(3,4-difluorophenoxy)phenoxy]butyl]-1,2,3,6-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 398126-80-2 CAPLUS
CN Pyridine, 2-[4-[4-(3,6-dihydro-1(2H)-pyridinyl)butoxy]phenoxy]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L10 ANSWER 17 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)


IT 287480-16-4P 398126-31-3P 398126-84-6P
RI: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of cyclic amine derivs. as remedies for obesity and diabetes)
RN 287480-16-4 CAPLUS
CN Pyridine, 1,2,3,6-tetrahydro-1-[3-[4-[4-(trifluoromethyl)phenoxy]phenoxy]propyl]- (9CI) (CA INDEX NAME)



RN 398126-31-3 CAPLUS
CN Pyridine, 1,2,3,6-tetrahydro-1-[3-[4-[4-(trifluoromethyl)phenyl)methyl]phenoxy]propyl]- (9CI) (CA INDEX NAME)




RN 398126-84-6 CAPLUS
CN Pyridinium, 1-[3-[4-[4-(trifluoromethyl)phenoxy]phenoxy]propyl]-, chloride (9CI) (CA INDEX NAME)



● Cl⁻

G1

Kamal Saeed



AB The title compds. I [A1 = (CH2)p; A is aryl, etc. (further details on A are given); X = O, etc.; m is an integer of 0 to 4; n is an integer of 1 to 6; and p is an integer of 1 to 3] are prep'd. Two compds. of this invention at 80 mg/kg s. c. for 7 days caused significant body wt. decrease in mice. Formulations are given.


REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS

FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

ACCESSION NUMBER: 2002:122935 CAPLUS
DOCUMENT NUMBER: 136:184117
TITLE: Preparation of triamine derivative melanocortin receptor ligands
INVENTOR(S): Watson-Straughan, Karen J.; Gahman, Timothy C.; Qi, Ming; Hamashin, Christie; MacDonald, James E.; Green, Michael J.; Holme, Kevin R.; Griffith, Michael C.
PATENT ASSIGNEE(S): Lion Bioscience A.-G., Germany
SOURCE: PCT Int. Appl., 169 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002012166	A2	20020214	WO 2001-EP8417	20010720
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GN, GO, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.: US 2000-632928 A 20000804				
IT 398482-33-2P				
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
(prepn. of triamine deriv. melanocortin receptor ligands)				
RN 398482-33-2 CAPLUS				
CN INDEX NAME NOT YET ASSIGNED				

Absolute stereochemistry.




AB Triamine deriv. melanocortin (MC) receptor ligands
R2R3NCH2CH2NHCH2(CH2)nR [R = (un)substituted Ph or cyclohexyl; n = 0-2; R1 = H, (un)substituted alkyl, phenylalkyl, naphthylalkyl; when R2 is absent, R3 together with the attached nitrogen form a substituted heterocycle or cyclic alkylene; when R2 is H or (un)substituted alkyl, R3 is X(Y)CH, where X is H, (un)substituted alkyl, phenylalkyl, Ph or naphthyl and Y is Z(CH2)n (n = 1-6, Z = amino or protected amino)] or their pharmaceutically acceptable salts were prep'd. Data for libraries of

triamine deriva. and starting materials are tabulated. E.g., Boc-Asp(OMe)-OH (Boc = tert-butoxycarbonyl, Me = 9-fluorenylmethyl), Boc-Tyr(Et)-OH, 4-BrC6H4CH2CO2H, and cyclopropylamine (c-C3H5NH2) were applied to the synthesis of H2NCH2CH(CH2CH2NHCH2CH2CH2C6H4OEt-4)NHCH2CH2C6H4Br-4. The triamine deriva. of the invention exhibit a range of affinities and specificity for various MC receptors.

ACCESSION NUMBER: 2002:122767 CAPLUS
DOCUMENT NUMBER: 136:178014
TITLE: Aryl-substituted 1,1-diphosphonates for stimulating bone formation
INVENTOR(S): Niesor, Eric J.; Guyon-Gellin, Yves; Bentsen, Craig L.; Nguyen, Lan Mong; Phan, Hieu Trung
PATENT ASSIGNEE(S): Symphar S.A., Switz.
SOURCE: PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002011704	A2	20020214	WO 2001-EP8676	20010727
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GN, GO, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.: GB 2000-19272 A 20000804				
IT 84449-90-1. Raloxifene				
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
(aryl-substituted diphosphonates for stimulating bone formation)				
RN 84449-90-1 CAPLUS				
CN Methanone, [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)				




AB The invention provides the use of an aryl-substituted 1,1-diphosphonate for the manuf. of a medicament for stimulating bone formation. The aryl-substituted 1,1-diphosphonates of the invention are ALC(P03R1R2)(P03R3R4)(B)t where [A = Q1-Q3; X0 = H, C1-4 alkyl; X1-X3 = H, C1-8 (un)branched alkyl or alkoxy; X4 = H, C1-8 (un)branched alkyl, (un)substituted benzyl; X5 = H, C1-8 (un)branched alkyl; X6 = H, C1-4 alkyl; q = 0, 1; R1-R4 = H, C1-8 (un)branched or cyclic alkyl, or R1, R2 and R3 and R4 may form C2-8 alkylidenedioxy ring; L = CH=CH-CH2, (CH2)n, O(CH2)n, S, SO2, S(CH2)n, SO2(CH2)n (n = 1-7), or together with B, L is (CH=CH)k(CH2)dCH= (k = 0, 1); d = 0-4; B = H, C1-4 alkyl; t = 0, 1; with proviso(s)]. Synthesis of selected compds. is described.

L10 ANSWER 20 OF 5482 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:119576 CAPLUS
DOCUMENT NUMBER: 136:175419
TITLE: Silver halide photographic emulsion containing sensitizing dye
INVENTOR(S): Furuchi, Hideo
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 31 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002049113	A2	20020215	JP 2000-238643	20000807

IT 297753-85-6 320610-25-1 396659-16-8
396659-18-0
RL: MOA (Modifier or additive use); TEM (Technical or engineered material use); USES (Uses)
(photog. emulsion manuf. by adding sensitizing dye at state other than org. soln.)
RN 297753-85-6 CAPLUS
CN Benzoxazolium, 3-(3-phenoxypropyl)-2-[2-[[3-(3-phenoxypropyl)-5-phenyl-2(3H)-benzothiazolylidene]methyl]-1-butenyl]-5-phenyl-, bromide (9CI)
(CA INDEX NAME)




RN 320610-25-1 CAPLUS
CN Benzoxazolium, 3-(3-phenoxypropyl)-2-[2-[[3-(3-phenoxypropyl)-5-phenyl-2(3H)-benzothiazolylidene]methyl]-1-butenyl]-5-phenyl-, salt with 4-methylbenzenesulfonic acid (1:1) (9CI) (CA INDEX NAME)
CM 1
CRN 320610-24-0
CMF C49 H45 N2 O4

L10 ANSWER 20 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)
benzothiazolylidene]methyl]-5-phenyl-, salt with 4-methylbenzenesulfonic acid (1:1) (9CI) (CA INDEX NAME)
CM 1
CRN 396659-17-9
CMF C47 H43 N2 O2 S2




CM 2
CRN 16722-51-3
CMF C7 H7 O3 S




AB In manuf. of the photog. emulsion with light absorbance .gtoreq.60 at .lambda.max <500 nm or .gtoreq.100 at .lambda.max .gtoreq.500 nm, a sensitizing dye is added at the state other than soln. in an org. solvent.
The emulsion with multilayer adsorption of sensitizing dye shows stable spectral absorption and stability to coupler oil droplet dispersion.


L10 ANSWER 20 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)




CM 2
CRN 16722-51-3
CMF C7 H7 O3 S



RN 396659-16-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED
CM 1
CRN 396659-15-7
CMF C45 H41 N2 O4



CM 2
CRN 16722-51-3
CMF C7 H7 O3 S




RN 396659-18-0 CAPLUS
CN Benzothiazolium, 3-(4-phenoxybutyl)-2-[3-(4-phenoxybutyl)-5-phenyl-2(3H)-

L10 ANSWER 21 OF 5482 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:107338 CAPLUS
DOCUMENT NUMBER: 136:167378
TITLE: Preparation of 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta for therapeutic agents
INVENTOR(S): Gong, Leyi; Grupe, Andrew; Peltz, Gary Allen
PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.
SOURCE: PCT Int. Appl., 105 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002010158	A2	20020207	WO 2001-EP8293	20010718


W: AE, AG, AL, AM, AT, AU, AZ, BA, BS, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: MARPAT 136:167378
OTHER SOURCE(S):
IT 396090-83-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(intermediate; prepn. of (indolylphenyl)-1H-pyrroledione deriva. as inhibitors of glycogen synthase kinase-3.beta. for therapeutic agents)
RN 396090-83-8 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-(1-methyl-1H-indol-3-yl)-4-[3-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




IT 103808-70-4P 396090-84-9P 396090-85-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of (indolylphenyl)-1H-pyrroledione deriva. as


L10 ANSWER 21 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)
inhibitors of glycogen synthase kinase-3.beta. for therapeutic agents)
RN 103808-70-4 CAPLUS
CN Morpholine, 4-[2-(3-iodophenoxy)ethyl]- (9CI) (CA INDEX NAME)



RN 396090-84-9 CAPLUS
CN 1H-Pyrrole-2,5-dione, 1-methyl-3-(1-methyl-1H-indol-3-yl)-4-[3-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 396090-85-0 CAPLUS
CN 2,5-Furandione, 3-(1-methyl-1H-indol-3-yl)-4-[3-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




IT 396090-86-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of (indolylphenyl)-1H-pyrroledione derivs. as inhibitors of glycogen synthase kinase-3.beta. for therapeutic agents)

L10 ANSWER 21 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)
diabetes, atherosclerotic cardiovascular disease, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency, cancer, allergy, and asthma in a mammal. The present inhibitor of GSK-3.beta. is also used for the treatment of a disease characterized by an excess of CD4+Th2 cytokines, which is asthma, allergy or allergic rhinitis or for the treatment of a disease characterized by an excess IgE prodn., which is asthma, allergy or allergic rhinitis. The GSK-3.beta. inhibitor is preferably at least 10 fold more selective for GSK-3.beta. relative to PKC. Thus, Mitsunobu reaction of Me 3-hydroxyphenylacetate with 2-chloroethanol using Ph3P and diisopropyl azodicarboxylate in THF at room temp. overnight gave Me 3-(2-chloroethoxy)phenylacetate which was saponified with aq. LiOH and treated with AcOH to give 3-(2-chloroethoxy)phenylacetic acid (II) which was converted into 3-(1-methylindol-3-yl)-4-[3-(2-aminoethoxy)phenyl]-1H-pyrrole-2,5-dione (III) in 4 steps. III in vitro showed IC50 of 0.02 .mu.M against GSK-3.beta..

L10 ANSWER 21 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)
RN 396090-86-1 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-1-methyl-4-[3-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




GI



AB The title compds. [I; R1, R2 = H, alkyl, halogen, haloalkyl, alkylthio, HO, alkoxy, cyano, nitro, amino, acylamino, monoalkylamino, or dialkylamino; R3 represents hydrogen, alkyl, cycloalkyl, heteroalkyl, CHO, alkylcarbonyl, or (un)substituted phenyl; R4, R5 = H, alkyl, halogen, haloalkyl, alkylthio, hydroxy, alkoxy, cyano, nitro, amino, acylamino, monoalkylamino, or dialkylamino; R6 = heteroalkyl, heterocyclyl, heterocyclylalkyl, heteroalkyl-substituted heterocyclyl, heteroalkyl-substituted cycloalkyl, heterosubstituted cycloalkyl, OR8, -S(O)nR8 (wherein n = an integer from 0 to 2; and R8 is heteroalkyl, heteroalkyl, heterocyclyl, or heterocyclylalkyl), NR9R10 (wherein R9 = hydrogen, alkyl; R10 = heterosubstituted cycloalkyl, heteroalkyl, heteroalkyl, heterocyclyl, or heterocyclylalkyl), or -X-(alkylene)-Y-Z (wherein X = a covalent bond, O, NH, or S(O)n; where n = an integer from 0 to 2; Y = O, NH, or S and Z = heteroalkyl or SiR1(R12)(R13) (where R11, R12, R13 are independently hydrogen or alkyl)), or R6 together with adjacent R4 forms a methylenedioxy or ethylenedioxy group) or pharmaceutically acceptable salts thereof are prepd. Owing to the inhibitory activity against glycogen synthase kinase-3.beta. (GSK-3.beta.), these compds. may be used for the treatment of GSK-3.beta. mediated diseases. More specifically, they are used for the treatment of GSK-3.beta. mediated diseases selected from Alzheimer's disease, obesity,

L10 ANSWER 22 OF 5482 CAPLUS COPYRIGHT 2002 ACS
2001:107327 CAPLUS
DOCUMENT NUMBER: 136:167394
TITLE: Preparation of carboxamide compounds and their use as antagonists of a human 11CBY receptor
INVENTOR(S): Johnson, Christopher Norbert; Jones, Martin; O'Toole, Catherine Anne; Stemp, Geoffrey; Thewlis, Kevin Michael; Witty, David
PATENT ASSIGNEE(S): SmithKline Beecham P.L.C., UK
SOURCE: PCT Int. Appl., 77 pp.
CODEN: PIXX02
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:
PATENT NO. KIND DATE APPLICATION NO. DATE
WO 2002010146 A1 20020207 WO 2001-EP0637 20010726
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: GB 2000-18758 A 20000731
GB 2001-12544 A 20010523
OTHER SOURCE(S): MARPAT 136:167394
IT 394248-77-2P 394248-78-3P 394248-79-4P
395677-59-5P 395677-60-8P 395677-85-7P
395677-92-6P 395677-93-7P 395677-94-8P
395677-95-9P 395678-14-5P 395678-15-6P
395678-16-7P 395678-18-9P 395678-20-3P
395678-21-4P 395678-34-9P 395678-35-0P
395678-36-1P 395678-37-2P 395678-38-3P
395678-39-4P 395678-41-8P 395678-42-9P
395678-43-0P 395678-44-1P 395678-47-4P
395678-53-2P 395678-56-5P 395678-76-9P
395678-77-0P 395678-81-6P 395678-83-8P
395678-86-1P 395678-87-2P 395678-88-3P
395678-89-4P 395678-90-7P 395678-92-9P
395678-93-3P 395679-43-3P 395679-46-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of carboxamide compds. as antagonists of human 11CBY receptor)
RN 394248-77-2 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 394248-78-3 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-4'-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 394248-79-4 CAPLUS
CN Benzamide, N-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-4-(phenylamino)- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



RN 395677-59-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[3-methoxy-4-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 395677-60-8 CAPLUS
CN Benzamide, 4-cyclohexyl-N-[3-methoxy-4-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 395677-85-7 CAPLUS
CN Benzamide, 4-cyclohexyl-N-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A




RN 395677-92-6 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[3-methoxy-4-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 395677-93-7 CAPLUS
CN Benzamide, 4-cyclohexyl-N-[3-methoxy-4-(2-(1-piperidinyl)ethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 395677-94-8 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[4-[2-(hexahydro-1H-azepin-1-yl)ethoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 395677-95-9 CAPLUS
CN Benzamide, 4-cyclohexyl-N-[4-[2-(hexahydro-1H-azepin-1-yl)ethoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 395678-14-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[3-methoxy-4-[2-(1,2,4,5-tetrahydro-3H-benzazepin-1-yl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 395678-21-4 CAPLUS
CN Benzamide, 4-cyclohexyl-N-[3-methoxy-4-[2-(4-phenyl-1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 395678-34-9 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-ethenyl-N-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




PAGE 1-A




RN 395678-15-6 CAPLUS
CN Benzamide, 4-cyclohexyl-N-[3-methoxy-4-[2-(1,2,4,5-tetrahydro-3H-benzazepin-1-yl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 395678-16-7 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[4-[2-(3,4-dihydro-2(1H)-isoquinolinyl)ethoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 395678-18-9 CAPLUS
CN Benzamide, 4-cyclohexyl-N-[4-[2-(3,4-dihydro-2(1H)-isoquinolinyl)ethoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 395678-20-3 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[3-methoxy-4-[2-(4-phenyl-1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




PAGE 2-A

RN 395678-35-0 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)




PAGE 1-A




PAGE 2-A

L10 ANSWER 22 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)

RN 395678-36-1 CAPLUS
CN Benzamide,
N-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-4-(2-thienyl)-
(9CI) (CA INDEX NAME)




RN 395678-37-2 CAPLUS
CN Benzamide, 4-(6-methoxy-3-pyridinyl)-N-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




PAGE 1-A

L10 ANSWER 22 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)
CN Benzamide, 4-(2,4-dimethoxy-5-pyrimidinyl)-N-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




PAGE 1-A



PAGE 2-A


RN 395678-41-8 CAPLUS
CN Benzamide, 4-(2-benzofuranyl)-N-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




Kamal Saeed

L10 ANSWER 22 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 2-A



RN 395678-38-3 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2'-methyl- (9CI) (CA INDEX NAME)



PAGE 1-A




PAGE 2-A


RN 395678-39-4 CAPLUS

L10 ANSWER 22 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)

RN 395678-42-9 CAPLUS
CN Benzamide,
N-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-4-(3-thienyl)-
(9CI) (CA INDEX NAME)




RN 395678-43-0 CAPLUS
CN Benzamide,
4-(3-furanyl)-N-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-
(9CI) (CA INDEX NAME)




RN 395678-44-1 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2',4',6'-trimethyl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 395678-47-4 CAPLUS
 CN Benzamide, N-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-4-(1-piperidinyl)- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 395678-53-2 CAPLUS
 CN Benzamide, N-[3-methoxy-4-[2-(4-morpholinyl)ethoxy]phenyl]-3-phenoxy- (9CI) (CA INDEX NAME)




RN 395678-56-5 CAPLUS
 CN Benzamide, N-[3-methoxy-4-[2-(4-morpholinyl)ethoxy]phenyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



RN 395678-76-9 CAPLUS
 CN Benzamide, N-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-3-phenoxy- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 395678-77-0 CAPLUS
 CN Benzamide, N-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)


PAGE 2-A




RN 395678-81-6 CAPLUS
 CN Benzamide, N-[3-methoxy-4-[2-(1-piperidinyl)ethoxy]phenyl]-3-phenoxy- (9CI) (CA INDEX NAME)




RN 395678-83-8 CAPLUS
 CN Benzamide, N-[3-methoxy-4-[2-(1-piperidinyl)ethoxy]phenyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 395678-86-1 CAPLUS
CN Benzamide, N-[3-methoxy-4-[2-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethoxy]phenyl]-3-phenoxy- (9CI) (CA INDEX NAME)




RN 395678-87-2 CAPLUS
CN Benzamide, N-[3-methoxy-4-[2-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethoxy]phenyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 395678-88-3 CAPLUS
CN Benzamide, N-[4-[2-(3,4-dihydro-2(1H)-isoquinolinyl)ethoxy]-3-methoxyphenyl]-3-phenoxy- (9CI) (CA INDEX NAME)




RN 395678-89-4 CAPLUS
CN Benzamide, N-[4-[2-(3,4-dihydro-2(1H)-isoquinolinyl)ethoxy]-3-methoxyphenyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 395678-90-7 CAPLUS
CN Benzamide, N-[3-methoxy-4-[2-(4-phenyl-1-piperazinyl)ethoxy]phenyl]-3-phenoxy- (9CI) (CA INDEX NAME)




RN 395678-92-9 CAPLUS
CN Benzamide, N-[3-methoxy-4-[2-(4-phenyl-1-piperazinyl)ethoxy]phenyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 395679-42-2 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-ethyl-N-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 395679-43-3 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-N-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 395679-46-6 CAPLUS
CN Benzamide, 4-cyclohexyl-N-ethyl-N-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 395679-93-3 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-methoxy-N-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



IT 394248-91-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of carboxamide compds. as antagonists of human 11CBY receptor)
RN 394248-91-0 CAPLUS
CN Benzenamide, 4-bromo-N-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI)
(CA INDEX NAME)


PAGE 1-A





PAGE 2-A



IT 394248-90-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of carboxamide compds. as antagonists of human 11CBY receptor)
RN 394248-90-9 CAPLUS
CN Benzenamide, 3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)



GI




II

AB Title compds. [I; A = H, C1-6alkyl optionally substituted by hydroxyl, C1-6alkoxy, C1-6alkenyl, C1-6 acyl, halogeno, OH, CN, CF3; R3 = H, CH3, CH3CH2; R4 = arom. carbocycle, heterocycle; Z = O, S, NH, CH2, single bond, at the 3 or 4 position of R4 relative to the carbonyl group; R5 = arom. carbocycle, heterocycle; Q = XYNR1R2; X = O, S; Y = C2-4 alkylene, C5-6 cycloalkylene; R1, R2 independently = C1-6 alkyl, phenyl-C1-6 alkyl; R1R2 = 5-, 6-, 7-membered ring optionally contg. one or more heteroatom selected from O, S, N; etc.], pharmaceutically acceptable salts, and solvate are prepd. and as antagonists of a human 11CBY receptor. Title compds. and pharmaceutical compn. are useful in the treatment and/or

L10 ANSWER 22 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)
prophylaxis of one or more of the disorder, such as, major depression,
manic depression, anxiety, etc. Thus, the title compd. II was prepd.
from
2'-methyl-biphenyl-4-carboxylic acid and 4-(2-diisopropylamino-ethoxy)-3-
methoxy-phenylamine in DMF in the presence of
1-(3-dimethylaminopropyl)-3-
Et carbodiimide hydrochloride and 1-hydroxy-7-azabenzotriazole.
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT


L10 ANSWER 23 OF 5482 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:107318 CAPLUS
DOCUMENT NUMBER: 136:151163
TITLE: Preparation of indazole derivatives as JNK enzyme
inhibitors
INVENTOR(S): Bhagwat, Shripad S.; Satoh, Yoshitaka; Sakata, Steven
T.
PATENT ASSIGNEE(S): Signal Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 412 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002010137	A2	20020207	WO 2001-US23890	20010730
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.: US 2000-221799P P 20000731				
IT 395103-65-8P, 3-[4-[2-(Morpholin-4-yl)ethoxy]phenyl]-1H-indazole-5-carbonitrile 395104-34-4P, 1-[5-(1H-1,2,4-Triazol-3-yl)-1H-indazol-3-yl]-3-(2-piperazinoethoxy)benzene 395106-70-4P,				
3-[3-(2-Piperidinoethoxy)phenyl]-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carbonitrile 395106-71-5P, 3-[3-(2-Piperidinoethoxy)phenyl]-1-(perhydro-2H-pyran-2-yl)-1H-indazole-5-carboxamide				
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)				
(intermediate; prepn. of indazole derivs. as JNK enzyme inhibitors)				
RN 395103-65-8 CAPLUS				
CN 1H-Indazole-5-carbonitrile, 3-[4-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)				




RN 395104-34-4 CAPLUS
CN 1H-Indazole, 3-[3-[2-(1-piperazinyl)ethoxy]phenyl]-5-(1H-1,2,4-triazol-3-yl)- (9CI) (CA INDEX NAME)


L10 ANSWER 23 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 395106-70-4 CAPLUS
CN 1H-Indazole-5-carbonitrile, 3-[3-[2-(1-piperidinyl)ethoxy]phenyl]-1-(tetrahydro-2H-pyran-2-yl)- (9CI) (CA INDEX NAME)



RN 395106-71-5 CAPLUS
CN 1H-Indazole-5-carboxamide, 3-[3-[2-(1-piperidinyl)ethoxy]phenyl]-1-(tetrahydro-2H-pyran-2-yl)- (9CI) (CA INDEX NAME)




IT 395103-63-6P, 1-[5-(1H-1,2,3,4-Tetrazol-5-yl)-1H-indazol-3-yl]-4-(2-(morpholin-4-yl)ethoxy)benzene 395103-81-8P, 1-[5-(1H-1,2,4-Tetrazol-5-yl)-1H-indazol-3-yl]-3-(2-(morpholin-4-yl)ethoxy)benzene 395104-21-9P, 1-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]-3-(2-(morpholin-4-yl)ethoxy)benzene 395104-28-6P, 1-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]-3-(2-pyrrolidinoethoxy)benzene 395104-30-0P, 1-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]-3-(2-piperidinoethoxy)benzene 395104-32-2P, 1-[2-[3-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]phenoxy]ethyl]pyrrolidin-2-one 395104-35-5P, 1-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]-3-(2-piperazinylethoxy)benzene bis(trifluoroacetate) 395104-37-7P, 1-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]-3-(3-

L10 ANSWER 23 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)
piperidinopropoxy)benzene 395104-38-8P, 4-[2-[3-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]phenoxy]ethyl]-1-acetylpiperazine 395104-47-9P, 1-[5-(1H-1,2,4-Triazol-5-yl)-1H-indazol-3-yl]-3-(2-hexahydroazepinoethoxy)benzene 395106-69-1P, 3-[3-(2-Piperidinoethoxy)phenyl]-1H-indazole-5-carboxamide


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of indazole derivs. as JNK enzyme inhibitors)


RN 395103-63-6 CAPLUS
CN 1H-Indazole, 3-[4-[2-(4-morpholinyl)ethoxy]phenyl]-5-(1H-tetrazol-5-yl)- (9CI) (CA INDEX NAME)



RN 395103-81-8 CAPLUS
CN 1H-Indazole, 3-[3-[2-(4-morpholinyl)ethoxy]phenyl]-5-(1H-tetrazol-5-yl)- (9CI) (CA INDEX NAME)




RN 395104-21-9 CAPLUS
CN 1H-Indazole, 3-[3-[2-(4-morpholinyl)ethoxy]phenyl]-5-(1H-1,2,4-triazol-3-yl)- (9CI) (CA INDEX NAME)




RN 395104-28-6 CAPLUS
CN 1H-Indazole, 3-[3-[2-(1-pyrrolidinyl)ethoxy]phenyl]-5-(1H-1,2,4-triazol-3-yl)- (9CI) (CA INDEX NAME)


Kamal Saeed



RN 395104-30-0 CAPLUS
CN 1H-Indazole, 3-[3-(2-(1-piperidinyl)ethoxy)phenyl]-5-(1H-1,2,4-triazol-3-yl)- (9CI) (CA INDEX NAME)




RN 395104-32-2 CAPLUS
CN 2-Pyrrolidinone, 1-[2-[3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]phenoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 395104-35-5 CAPLUS
CN 1H-Indazole, 3-[3-(2-(1-piperazinyl)ethoxy)phenyl]-5-(1H-1,2,4-triazol-3-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 395104-34-4
CMP C21 H23 N7 O



CM 2



AB Indazole deriva., 3-R1A-5-R2-1H-indazoles (1), having activity as selective inhibitors of JNK are disclosed. In 1: A is a direct bond, -(CH2)a-, -(CH2)bCH:CH(CH2)c-, or -(CH2)bc.tplbond.C(CH2)c-; R1 is aryl, heteroaryl or heterocycle fused to Ph, each being optionally substituted with 1-4 R3; R2 is -R3, -R4, -(CH2)bc(O)R5, -(CH2)bc(O)OR5, -(CH2)bc(O)NR5R6, -(CH2)bc(O)NR5(CH2)cc(O)R6, -(CH2)bNR5C(O)R6, -(CH2)bNR5C(O)NR6R7, -(CH2)bNR5R6, -(CH2)bOR5, -(CH2)bSOdR5 or -(CH2)bSO2NR5R6. A is 1-6; b and c are the same or different and are

0-4; d is 0-2. R3 is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, -C(O)OR8, -C(O)R8, -C(O)NR8R9, -C(O)NR8OR9, -SO2NR8R9, -NR8SO2R9, -CN, -NO2, -NR8R9, -NR8C(O)R9, -NR8C(O)(CH2)bOR9, -NR8C(O)(CH2)bR9, -O(CH2)bNR5R9, or heterocycle fused to Ph. R4 is alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, each being optionally substituted with 1-4 R3, or R4 is halogen or hydroxy. R5, R6 and R7 are the same or different and are H, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of R5, R6 and R7 are optionally substituted with 1-4 R3. R8 and R9 are the same or different and at each occurrence independently H, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or R8 and R9 taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of R8, R9, and R8 and R9 taken together to form a heterocycle


are optionally substituted with 1-4 R3 with the proviso that: when A is a direct bond and R1 is Ph, R2 is not Me, methoxy, C(O)CH3 or C(O)H; when A is a direct bond and R1 is 4-Me-Ph, R2 is not Me; when A is a direct bond and R1 is 4-F-Ph, R2 is not trifluoromethyl; when A is a direct bond or -C.tplbond.C- and R1 is Ph, R2 is not -COOEt; and when A is a direct bond and R1 is 6,7-dimethoxyquinolin-1-yl, R2 is not hydroxy. Such compds. have utility in the treatment of a wide range of conditions that are responsive to JNK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compns. contg. one or more compds. of the above compds. Many of the claimed compds. have IC50 values

litoreq.0.5 .mu.M in the JNK2 assay, e.g.
5-[3-(4-fluorophenyl)-1H-indazol-3-yl]-2H-1,2,3,4-tetrazole. Although the methods of prepn. are not claimed, >400 example prepn. are included.


CRN 76-05-1
CMP C2 H F3 O2




RN 395104-37-7 CAPLUS
CN 1H-Indazole, 3-[3-[3-(1-piperidinyl)propoxy]phenyl]-5-(1H-1,2,4-triazol-3-yl)- (9CI) (CA INDEX NAME)



RN 395104-38-8 CAPLUS
CN Piperazine, 1-acetyl-4-[2-[3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]phenoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 395104-47-9 CAPLUS
CN 1H-Indazole, 3-[3-[2-(hexahydro-1H-azepin-1-yl)ethoxy]phenyl]-5-(1H-1,2,4-triazol-3-yl)- (9CI) (CA INDEX NAME)



RN 395106-69-1 CAPLUS
CN 1H-Indazole-5-carboxamide, 3-[3-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)


ACCESSION NUMBER: 2002:107312 CAPLUS
DOCUMENT NUMBER: 136:167389
TITLE: Preparation of pyrrole, indole, thiophene, pyrazole, imidazole, and isothiazole derivatives as inhibitors of transforming growth factor-beta (TGF-beta.)
INVENTOR(S): Tokunaga, Teruhisa; Hume, William Ewan; Kitoh, Makoto;
Nagata, Ryu
PATENT ASSIGNEE(S): Sumitomo Pharmaceuticals Co., Ltd., Japan
SOURCE: JCT Int. Appl., 215 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002010131	A1	20020207	WO 2001-JP6495	20010727
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			


PRIORITY APPLN. INFO.: JP 2000-229423 A 20000728
OTHER SOURCE(S): MARPAT 136:167389
IT 397325-07-4P, 2-[[2-(4-(2-(Morpholino)ethoxy)benzoyl)pyrrol-1-yl)methyl]quinoxaline 397325-13-2P, 3-[[2-(4-(2-(Morpholino)ethoxy)benzoyl)pyrrol-1-yl)methyl]quinoline 397326-04-4P, 2-[3-(4-Methyl-2-(4-(2-(morpholino)ethoxy)benzoyl)-1-pyrrolyl)-1-propen-1-yl]-5-chlorobenzoic acid sodium salt 397326-06-4P, N-Methyl-2-[3-(4-methyl-2-(4-(2-(morpholino)ethoxy)benzoyl)-1-pyrrolyl)-1-propen-1-yl]-5-chlorobenzamide hydrochloride 397326-49-7P, 2-[3-(4-Methyl-2-(4-(2-(morpholino)ethoxy)benzoyl)-1-pyrrolyl)-1-propen-1-yl]-5-chloro-1-methoxybenzene
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

[prepn. of pyrrole, indole, thiophene, pyrazole, imidazole, and isothiazole deriva. as inhibitors of transforming growth factor-beta. and fibroid inhibitors for organs or tissues]


RN 397325-07-4 CAPLUS
CN Methanone, [4-[2-(4-morpholinyl)ethoxy]phenyl][1-(2-quinoxalinylmethyl)-1H-pyrrol-2-yl]- (9CI) (CA INDEX NAME)



RN 397325-13-2 CAPLUS
CN Methanone, [4-[2-(4-morpholinyl)ethoxy]phenyl][1-(3-quinolinylmethyl)-1H-pyrrol-2-yl]- (9CI) (CA INDEX NAME)




RN 397326-04-4 CAPLUS
CN Benzoic acid, 5-chloro-2-[3-[4-methyl-2-[4-[2-(4-morpholinyl)ethoxy]benzoyl]-1H-pyrrol-1-yl]-1-propenyl]-, sodium salt (9CI) (CA INDEX NAME)




IT 397325-11-0P, 3-[[2-(4-(4-(Phthalimido)butoxy)benzoyl)pyrrol-1-yl]methyl]quinoline
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of pyrrole, indole, thiophene, pyrazole, imidazole, and isothiazole derivs. as inhibitors of transforming growth factor-.beta. and fibroid inhibitors for organs or tissues)

RN 397325-11-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




GI




● Na

RN 397326-06-6 CAPLUS
CN Benzamide, 5-chloro-N-methyl-2-[3-[4-methyl-2-[4-[2-(4-morpholinyl)ethoxy]benzoyl]-1H-pyrrol-1-yl]-1-propenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 397326-49-7 CAPLUS
CN Methanone, [1-[3-(4-chloro-2-methoxyphenyl)-2-propenyl]-4-methyl-1H-pyrrol-2-yl][4-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



AB The title compds. represented by the following formula (I) or pharmaceutically acceptable salts of these [wherein ring Z represents an optionally substituted pyrrole, indole, thiophene, pyrazole, benzene, imidazole, or isothiazole; W2 represents CO, SO2, CONR (R = H, alkyl), optionally substituted C1-4 alkylene or C2-4 alkenylene; Ar2 represents optionally substituted aryl or heteroaryl; and W1 and Ar1 mean the following: (1) W1 represents optionally substituted C1-4 alkylene or C2-4 alkenylene, Ar1 represents bicyclic heteroaryl having one to four N atoms or (2) W1 represents optionally substituted C2-5 alkylene, C2-5 alkenylene, C2-5 alkynylene, or -Y-W3 (wherein Y = O or cycloalkanedyl; W3 = optionally substituted C1-5 alkylene, C2-5 alkenylene, or C2-5 alkynylene). Ar represents optionally substituted aryl or monocyclic heteroaryl substituted at ortho or meta position by CO2H, alkoxycarbonyl, optionally alkyl-substituted carbamoyl, cyclic aminocarbonyl, alkylsulfonylcarbonyl, arylsulfonylcarbonyl, alkylsulfonyl, etc.] or prodrugs or pharmaceut. acceptable salts thereof are prepd. These compds. are useful as fibroid inhibitors for organs or tissues. Thus, bromination of 3-(4-chloro-2-methoxycarbonylphenyl)-2-propenol (prepn. given) by N-bromosuccinimide and PPh3 in CH2Cl2 at 0.degree. for 10 min gave 3-(4-chloro-2-methoxycarbonylphenyl)-2-propenyl bromide (II). A THF soln. of 2-(4-methylbenzoyl)pyrrole was added dropwise to a suspension of NaH in THF and the resulting soln. was slowly added dropwise to a THF soln. of II at 55.degree. and stirred for 2 h to give 2-[3-[2-(4-methylbenzoyl)-1-pyrrolyl]-1-propen-1-yl]-5-chlorobenzoic acid Me ester which was saponified with aq. NaOH in methanol and acidified with aq. HCl to give III (R = Me, R1 = H). In a kidney fibroid model using a rat Thy-1 nephritis model, administration of III.Na (R = Me, R1 = H) at 15 mg/kg and Thy-1 (one of surface antigens of thymocyte) to rats lowered the level of hydroxyproline (fibroid index) in kidney compared to the control group administered only with Thy-1. III.Na (R = 2-morpholinoethoxy, R1 = Me) at 3 .mu.M in vitro inhibited the TGF-.beta.-induced prodn. of proteoglycan in MRK-49F rat fibroblast cells by 99%.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE


FORMAT

L10 ANSWER 25 OF 5482 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 2002:107097 CAPLUS
 DOCUMENT NUMBER: 136:145266
 TITLE: Anticonvulsant derivatives useful for the treatment of depression
 INVENTOR(S): Plata-Salaman, Carlos; Bacaltchuk, Josue; Prado-Lima, Pedro A. S.
 PATENT ASSIGNEE(S): Ortho-McNeil Pharmaceutical, Inc., USA
 SOURCE: PCT Int. Appl., 25 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002009694	A1	20020207	WO 2001-US23786	20010727

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OL, OM, OS, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2000-222489P P 20000802
 OTHER SOURCE(S): MARPAT 136:145266
 IT 83366-66-9, Nefazodone
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (anticonvulsant derivs. useful for treatment of depression)
 RN 83366-66-9 CAPLUS
 CN 3H-1,2,4-Triazol-3-one, 2-[3-(4-(3-chlorophenyl)-1-piperazinyl)propyl]-5-ethyl-2,4-dihydro-4-(2-phenoxyethyl)- (9CI) (CA INDEX NAME)




AB Anticonvulsant derivs. of formula (I) for the treating depression as monotherapy or combination therapy are disclosed. Wherein X is CH₂ or oxygen; R₁ is hydrogen or alkyl; and R₂, R₃, R₄ and R₅ are independently hydrogen or lower alkyl and, when X is CH₂, R₄ and R₅ may be alkene groups joined to form a benzene ring and, when X is oxygen, R₂ and R₃ and/or R₄ and R₅ together may be a methylenedioxy group of the following formula (II); wherein R₆ and R₇ are the same or different and are hydrogen, lower alkyl or are alkyl and are joined to form a cyclopentyl or cyclohexyl ring.
 REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L10 ANSWER 26 OF 5482 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 2002:104615 CAPLUS
 DOCUMENT NUMBER: 136:145283
 TITLE: Use of an estrogen agonist/antagonist for treating cataracts
 INVENTOR(S): Rosati, Robert Louis
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA
 SOURCE: Eur. Pat. Appl., 21 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 117787	A2	20020206	EP 2001-306066	20010713

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO
 US 2002016340 A1 20020207 US 2001-915020 20010725
 PRIORITY APPLN. INFO.: US 2000-221441P P 20000728
 OTHER SOURCE(S): MARPAT 136:145283
 IT 198481-33-3, TSE 424
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (TSE 424; estrogen agonist/antagonist for treating cataracts)
 RN 198481-33-3 CAPLUS
 CN 1H-Indol-5-ol, 1-[4-(2-(hexahydro-1H-azepin-1-yl)ethoxy)phenyl]methyl-2-(4-hydroxyphenyl)-3-methyl-, monoacetate (salt) (9CI) (CA INDEX NAME)
 CM 1
 CRN 198481-32-2
 CMF C30 H34 N2 O3




CM 2
 CRN 64-19-7
 CMF C2 H4 O2

L10 ANSWER 25 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)


L10 ANSWER 26 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)



IT 84449-90-1, Raloxifene 84449-90-1D, Raloxifene, derivs. and isomers 116057-75-1, Idoxifene 116057-75-1D, Idoxifene, derivs. and isomers 151533-34-5 151533-34-5D, derivs. and isomers 166975-07-1 166975-07-1D, derivs. and isomers 175737-59-4 175737-59-4D, derivs. and isomers 182167-02-8, EM-652 182167-02-8D, EM-652, derivs. and isomers 182167-03-9, EM-800 182167-03-9D, EM-800, derivs. and isomers 182167-04-0 182167-04-0D, derivs. and isomers 198481-33-3D, TSE 424, derivs. and isomers RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (estrogen agonist/antagonist for treating cataracts)
 RN 84449-90-1 CAPLUS
 CN Methanone, [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 84449-90-1 CAPLUS
 CN Methanone, [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 116057-75-1 CAPLUS
 CN Pyrrolidine, 1-[2-[4-[(1E)-1-(4-iodophenyl)-2-phenyl-1-butenyl]phenoxy]ethyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.

L10 ANSWER 26 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 116057-75-1 CAPLUS
CN Pyrrolidine, 1-[2-[4-{{1E}}-1-(4-iodophenyl)-2-phenyl-1-butenyl]phenoxy]ethyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 151533-34-5 CAPLUS
CN 2H-1-Benzopyran-7-ol, 3-(4-hydroxyphenyl)-4-methyl-2-[4-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)

L10 ANSWER 26 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 175737-59-4 CAPLUS
CN 2-Naphthalenol, 6-(4-hydroxyphenyl)-5-[[4-[2-(1-piperidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 175737-59-4 CAPLUS
CN 2-Naphthalenol, 6-(4-hydroxyphenyl)-5-[[4-[2-(1-piperidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)


L10 ANSWER 26 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 151533-34-5 CAPLUS
CN 2H-1-Benzopyran-7-ol, 3-(4-hydroxyphenyl)-4-methyl-2-[4-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 166975-07-1 CAPLUS
CN Methanone, [4-[2-(2-azabicyclo[2.2.1]hept-2-yl)ethoxy]phenyl] [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl]- (9CI) (CA INDEX NAME)




RN 166975-07-1 CAPLUS
CN Methanone, [4-[2-(2-azabicyclo[2.2.1]hept-2-yl)ethoxy]phenyl] [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl]- (9CI) (CA INDEX NAME)

L10 ANSWER 26 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 182167-02-8 CAPLUS
CN 2H-1-Benzopyran-7-ol, 3-(4-hydroxyphenyl)-4-methyl-2-[4-[2-(1-piperidinyl)ethoxy]phenyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 182167-02-8 CAPLUS
CN 2H-1-Benzopyran-7-ol, 3-(4-hydroxyphenyl)-4-methyl-2-[4-[2-(1-piperidinyl)ethoxy]phenyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).

L10 ANSWER 26 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 182167-03-9 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 4-[(2S)-7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-(2-(1-piperidinyl)ethoxy)phenyl]-2H-1-benzopyran-3-yl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 182167-03-9 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 4-[(2S)-7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-(2-(1-piperidinyl)ethoxy)phenyl]-2H-1-benzopyran-3-yl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 182167-04-0 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 4-[(2S)-7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-(2-(1-piperidinyl)ethoxy)phenyl]-2H-1-benzopyran-3-yl]phenyl ester (9CI) (CA INDEX NAME)


L10 ANSWER 26 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)

CRN 64-19-7
CMP C2 H4 O2




AB The invention provides methods, pharmaceutical compns., and kits useful in treating cataracts. The compns. are comprised of an estrogen agonist/antagonist and a pharmaceutically acceptable vehicle, carrier, or diluent. The compns. and methods of treatment are effective while substantially reducing the concomitant liability of adverse effects assocd. with estrogen administration.

L10 ANSWER 26 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 182167-04-0 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 4-[(2S)-7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-(2-(1-piperidinyl)ethoxy)phenyl]-2H-1-benzopyran-3-yl]phenyl ester (9CI) (CA INDEX NAME)



RN 198481-33-3 CAPLUS
CN 1H-Indol-5-ol, 1-[[4-(2-(hexahydro-1H-azepin-1-yl)ethoxy)phenyl]methyl]-2-(4-hydroxyphenyl)-3-methyl-, monoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 198481-32-2
CMP C30 H34 N2 O3



CM 2


L10 ANSWER 27 OF 5482 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:98530 CAPLUS
DOCUMENT NUMBER: 136:158912
TITLE: Aliphatic group-substituted aminopyridinium derivative
INVENTOR(S): for controlling of liquid crystal tilt angle
PATENT ASSIGNEE(S): Nishikawa, Naoyuki; Ogawa, Masataka; Kawada, Tadaashi
SOURCE: Fuji Photo Film Co., Ltd., Japan
Jpn. Kokai Tokkyo Koho, 12 pp.
CODEN: JKKXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002037777	A2	20020206	JP 2000-221115	20000721




OTHER SOURCE(S): MARPAT 136:158912
IT 395071-17-7P
RL: IMP (Industrial manufacture); MOA (Modifier or additive use); PREP (Preparation); USES (Uses)
(aliph. group-substituted aminopyridinium deriv. for controlling of liq. crystal tilt angle)
RN 395071-17-7 CAPLUS
CN Pyridinium, 1-[3-[(4'-methoxy[1,1'-biphenyl]-4-yl)oxy]propyl]-4-(1-pyrrolidinyl)-, iodide (9CI) (CA INDEX NAME)

PAGE 1-A





GI



AB The aminopyridinium deriv. is that represented as I (L1 = C1-20 hydrocarbylene; R1, R2 = C1-8 aliph. group; R1-R2 may form N-contg. heterocycle; X = anion; Z1 = Ph substituted with carboxyl, (cyano-, halogen-, nitro-, C1-10 alkyl-, or C1-10 alkoxy-substituted) Ph, C1-10 alkyl, C1-10 alkoxy, C2-11 alkoxycarbonyl, C7-13 aryloxy carbonyl, C4-13 alkoxycarbonylvinyl, C9-15 aryloxy carbonylvinyl], II (L2 = C1-20 alkylene, C1-20 hydrocarbylene involving alkylene, O, S, CO, SO2, NR, alkenylene, alkynylene, arylene; R = H, C1-6 alkyl; R3, R4 = C1-8 aliph. group; R3-R4 may form N-contg. heterocycle; Z2 = carboxyl, (p-cyano-, p-halogeno-, p-nitro-, p-C1-10 alkyl-, or p-C1-10 alkoxy-substituted) Ph, C1-10 alkyl, C1-10 alkoxy, C2-11 alkoxycarbonyl, C7-13 aryloxy carbonyl, C4-13 alkoxycarbonylvinyl, C9-15 aryloxy carbonylvinyl], III (Y = C4-20 F-substituted alkyl, C6-30 alkyl having .gtoreq.3-branched C, steroid-including aliph. group; L1, R1, and R2 are the same in I), or IV (L3 = L2; R3, R4 are the same in II; Y is the same in III). Tilt angles of liq. crystals, e.g., discotic liq. crystal, can be controlled by the deriva.

L10 ANSWER 28 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)
preventing an individual at risk for a vascular event, disease or disorder
by administering a SSRI.

ACCESSION NUMBER: 2002:90620 CAPLUS
DOCUMENT NUMBER: 136:112659
TITLE: Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors and treatment of cardiovascular disease
INVENTOR(S): Serebruany, Victor L.; Gurbel, Paul A.; O'Connor, Christopher M.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 22 pp., Cont.-in-part of U.S. 6,245,782.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002013343	A1	20020131	US 2001-804689	20010312
US 6245782	B1	20010612	US 1999-312987	19990517

PRIORITY APPLN. INFO.: US 1999-312987 A2 19990517

IT 83366-66-9, Nefazodone 83366-66-9D, Nefazodone,

metabolites

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)


(inhibition of platelet activation with selective serotonin reuptake

inhibitors and treatment of cardiovascular disease)

RN 83366-66-9 CAPLUS

CN 3H-1,2,4-Triazol-3-one, 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-


ethyl-2,4-dihydro-4-(2-phenoxyethyl)- (9CI) (CA INDEX NAME)



RN 83366-66-9 CAPLUS

CN 3H-1,2,4-Triazol-3-one, 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-

ethyl-2,4-dihydro-4-(2-phenoxyethyl)- (9CI) (CA INDEX NAME)



AB The present invention pertains to methods for reducing the platelet activation state in an individual comprising administering a selective serotonin reuptake inhibitor (SSRI). The platelet activation state is reduced upon administering a SSRI, as measured by one or more platelet activation markers. The invention also relates to methods for treating or

ACCESSION NUMBER: 2002:90616 CAPLUS
DOCUMENT NUMBER: 136:129080
TITLE: Antidepressant effect of norepinephrine uptake 2 inhibitors, and combined medications including them
INVENTOR(S): Schildkraut, Joseph J.; Mooney, John J.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 6 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002013312	A1	20020131	US 2001-811235	20010316
US 6245782	B1	20010612	US 1999-312987	19990517

PRIORITY APPLN. INFO.: US 2000-189828 P 20000316

IT 83366-66-9, Nefazodone 83366-66-9D, Nefazodone,

metabolites

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)


(norepinephrine uptake 2 inhibitors, and combined medications

including them, for antidepressants)

RN 83366-66-9 CAPLUS

CN 3H-1,2,4-Triazol-3-one, 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-


ethyl-2,4-dihydro-4-(2-phenoxyethyl)- (9CI) (CA INDEX NAME)



AB Norepinephrine uptake 2 inhibitors (or their precursors) are administered to enhance the effect of norepinephrine reuptake inhibitors and other antidepressants. The uptake 2 inhibitor may be combined in a single medication with a norepinephrine reuptake inhibitor, such as imipramine, desipramine, or reboxetine, in order to inhibit both uptake mechanisms. The norepinephrine uptake 2 inhibitors may also be combined with MAO inhibitors or with selective serotonin reuptake inhibitors. Alternatively, the norepinephrine uptake 2 inhibitors may be useful antidepressants in their own right, without the need for co-administration of other antidepressants. One class of norepinephrine uptake 2 inhibitors is normetanephrine (the O-methylated metabolite of norepinephrine) and normetanephrine precursors (such as 3-(4-hydroxy-3-methoxyphenyl)serine (4H-3MePS), particularly L-threo-3-(4-H-3MePS)) that are transported to the brain where they are converted into normetanephrine, thereby enhancing the effect of other antidepressants. For example, the invention enhances the antidepressant effect of norepinephrine reuptake inhibitors.

L10 ANSWER 30 OF 5482 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:89837 CAPLUS
DOCUMENT NUMBER: 136:129066
TITLE: Method for enhancing bisphosphonate therapy bone mineral density gain with raloxifene
INVENTOR(S): Muchmore, Douglas Boyer; Lu, Yili
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002007733	A2	20020131	WO 2001-US16515	20010705
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, VU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.: US 2000-219286P P 20000719 US 2000-233737P P 20000919				
IT 82640-04-8, Raloxifene hydrochloride 84449-90-1, Raloxifene 84449-90-1D, Raloxifene, salts or solvates RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (method for enhancing bisphosphonate therapy bone mineral d. gain with raloxifene)				
RN 82640-04-8 CAPLUS				
CN Methanone, [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)				




● HCl

RN 84449-90-1 CAPLUS
CN Methanone, [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)

L10 ANSWER 30 OF 5482 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 84449-90-1 CAPLUS
CN Methanone, [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



AB This invention relates to a method for enhancing bone mineral d. gain acquired through previous bisphosphonate therapy comprising administering to a human in need thereof a bone-enhancing amt. of raloxifene or a pharmaceutically acceptable salt or solvate thereof.

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

135.03

417.92

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-18.59

-18.59

STN INTERNATIONAL LOGOFF AT 09:34:58 ON 19 MAR 2002

Connection closed by remote host

09922631

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:sssptal626kas

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *
SESSION RESUMED IN FILE 'REGISTRY' AT 12:54:01 ON 11 JUL 2002
FILE 'REGISTRY' ENTERED AT 12:54:01 ON 11 JUL 2002
COPYRIGHT (C) 2002 American Chemical Society (ACS)
COST IN U.S. DOLLARS

	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	426.54	426.75

=> file reg

COST IN U.S. DOLLARS

	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	426.92	427.13

FILE 'REGISTRY' ENTERED AT 12:54:36 ON 11 JUL 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 10 JUL 2002 HIGHEST RN 438186-75-5
DICTIONARY FILE UPDATES: 10 JUL 2002 HIGHEST RN 438186-75-5

TSCA INFORMATION NOW CURRENT THROUGH January 7, 2002

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES
for more information. See STNnote 27, Searching Properties in the CAS
Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=>

Uploading C:\Program Files\Stnexp\Queries\099223112.str

L12 STRUCTURE UPLOADED

=> que L12

L13 QUE L12


=> d

L13 HAS NO ANSWERS

L12 STR

Kamal Saeed

09922631



Structure attributes must be viewed using STN Express query preparation.
L13 QUE ABB=ON PLU=ON L12

=> s l12

SAMPLE SEARCH INITIATED 12:55:01 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 144 TO ITERATE

100.0% PROCESSED 144 ITERATIONS
SEARCH TIME: 00.00.02

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 2161 TO 3599
PROJECTED ANSWERS: 0 TO 0

L14 0 SEA SSS SAM L12

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=>

Uploading C:\Program Files\Stnexp\Queries\099223112.str

L15 STRUCTURE UPLOADED


=> que L15

L16 QUE L15

=> d

L16 HAS NO ANSWERS
L15 STR

09922631



Structure attributes must be viewed using STN Express query preparation.
L16 QUE ABB=ON PLU=ON L15

=> s l15

SAMPLE SEARCH INITIATED 12:56:18 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 3141 TO ITERATE

31.8% PROCESSED 1000 ITERATIONS 2 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 59460 TO 66180
PROJECTED ANSWERS: 2 TO 275

L17 2 SEA SSS SAM L15

=> file caplus
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
1.14	428.27

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 12:56:27 ON 11 JUL 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing

Kamal Saeed

09922631

of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 11 Jul 2002 VOL 137 ISS 2
FILE LAST UPDATED: 10 Jul 2002 (20020710/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> s l17

L18 1 L17

=> d ibib abs hitstr tot


09922631

L18 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 2001:687446 CAPLUS
 DOCUMENT NUMBER: 135:242131
 TITLE: Preparation of thiophenecarboxamides and analogs as protease inhibitors
 INVENTOR(S): Illig, Carl R.; Subasinghe, Nalin L.; Hoffman, James B.; Wilson, Kenneth J.; Rudolph, M. Jonathan;
 Marugen,
 Juan Jose
 PATENT ASSIGNEE(S): 3-Dimensional Pharmaceuticals, Inc., USA
 SOURCE: U.S., 108 pp., Cont.-in-part of U. S. Ser. No. 247,062.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6291514	B1	20010918	US 1999-372748	19990811
US 2001031781	A1	20011018	US 2001-828783	20010410
US 6403633	B2	20020611		

 PRIORITY APPLN. INFO.:
 US 1998-74110P P 19980209
 US 1999-247062 A2 19990209
 US 1999-372748 A1 19990811
 OTHER SOURCE(S): MARPAT 135:242131
 GI

L18 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS (Continued)
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of thiophenecarboxamides and analogs as protease inhibitors)
 RN 237381-99-6 CAPLUS
 CN Piperidine, 1-[(3-[2-[5-(aminoiminomethyl)-2-(methylthio)-3-thienyl]-4-thiazolyl]phenoxy]acetyl]-4-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT



AB The title compds. [I; X = S; Y = a covalent bond, NH; Z = NR5R6; R1 = H, NH2, OH, halo; R2 = alkylsulfonylamino, aralkylsulfonylamino, arylsulfonylamino, etc.; R3 = H, alkylthio, alkyl, etc.; R4-R6 = H, alkyl, aryl, etc.] which are potent inhibitors of proteases, esp. trypsin-like serine proteases, such as chymotrypsin, trypsin, plasmin and urokinase, were prepd. and formulated. Thus, cyclocondensation of Me 4-(aminothioxomethyl)-5-methylthiophene-2-carboxylate with 4'-phenyl-2-bromoacetophenone followed by treatment of the resulting intermediate with with NH4Cl/Me3Al afforded the title compd. II.HCl.

Data for biol. activity of I were given.
 IT 237381-99-6P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological)

09922631

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

4.79

433.06

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-0.62

-0.62

STN INTERNATIONAL LOGOFF AT 12:57:02 ON 11 JUL 2002

Kamal Saeed